



National Cancer Drugs Fund List

(Including list of NICE approved and baseline funded drugs/indications from 1st April 2016 with criteria for use)

ver1.101
31-Aug-18

National Cancer Drugs Fund (CDF) List

NHS England INFORMATION READER BOX		
Directorate		
Medical	Operations and Information	Specialised Commissioning
Nursing	Trans. & Corp. Ops.	Commissioning Strategy
Finance		
Publications Gateway Reference: 05605		
Document Purpose	Policy	
Document Name	National Cancer Drug Fund List	
Author	NHS England Cancer Drugs Fund Team	
Publication Date	29 July 2016	
Target Audience	Foundation Trust CEs , Medical Directors, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs, Patients; Patient Groups; Charities; Pharmaceutical Industry	
Additional Circulation List		
Description		
Cross Reference	National Cancer Drug Fund decision summaries	
Superseded Docs (if applicable)	National Cancer Drug Fund List (as updated July 2015)	
Action Required	N/A	
Timing / Deadlines (if applicable)	N/A	
Contact Details for further information	NHS England Cancer Drugs Fund Team Skipton House 80 London Road London SE1 6LH england.cdfteam@nhs.net	
Document Status		
This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.		

National Cancer Drugs Fund (CDF) List

A. National CDF List

Notes: This list should be read in conjunction with 'Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) A new deal for patients, taxpayers and industry' published by NHS England on 8 July 2016 at www.england.nhs.uk/ourwork/cancer/cdf

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
ALE1_v1.0	Alectinib	Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer where the following criteria are met:	<ol style="list-style-type: none"> The application is made by and the first cycle of systemic anti-cancer therapy with alectinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy The patient has a histologically or cytologically confirmed diagnosis of stage IIIB or IV non small cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement The patient has received no previous ALK-targeted therapy The patient has received no previous cytotoxic chemotherapy for locally advanced or metastatic non small cell lung cancer ie no previous systemic treatment except when this has been given as neoadjuvant or adjuvant therapy or concurrently with radiotherapy Alectinib will be used only as single-agent therapy The patient has an ECOG performance status of 0 or 1 or 2 The patient either has no brain metastases or, if the patient has brain metastases, the patient is symptomatically stable prior to starting alectinib The patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle Alectinib will be otherwise used as set out in its Summary of Product Characteristics In cases of intolerance to alectinib, either ceritinib or crizotinib is to be used only if the patient has not had progressive disease whilst on alectinib. Neither ceritinib nor crizotinib are to be used following disease progression on alectinib as there is no current clear evidence to support treatment with ceritinib or crizotinib after disease progression on alectinib. Alectinib cannot be used in any line other than 1st line as the manufacturer chose not to make a submission to NICE for its licensed indication for use after crizotinib 	From 28-Jun-18			No	n/a	Yes	Yes	No	06-Nov-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
ARS1_v1.1	Arsenic trioxide	Arsenic trioxide for treating newly diagnosed low to intermediate risk acute promyelocytic leukaemia in ADULTS where all the following criteria are met:	<p>1. An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient is an ADULT and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene</p> <p>3. The patient is newly diagnosed with acute promyelocytic leukaemia</p> <p>4. The patient has low to intermediate risk acute promyelocytic leukaemia (white cell count $\leq 10 \times 10^9/L$) and has not received any chemotherapy for this. Patients with high risk acute promyelocytic leukaemia are not funded for treatment with arsenic trioxide</p> <p>5. The patient will be treated with induction treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA)</p> <p>6. Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 60, arsenic trioxide will be discontinued</p> <p>7. As consolidation therapy, a maximum of 4 cycles of arsenic trioxide will be prescribed, each cycle being 4 weeks on treatment followed by 4 weeks off therapy</p> <p>8. The dosing and schedule of administration of arsenic trioxide will be either in accordance with that described in the Summary of Product Characteristics (SPC) or that used in the UK NCRI AML17 trial as reported in Lancet Oncology 2015; 16:1295-1305.</p> <p>If the AML17 dosing and schedule is used, hospital Trust policy regarding unlicensed treatments should be followed</p> <p>9. The treating team is aware of the risk of and the treatment for * APL differentiation syndrome * QT interval prolongation and the need for monitoring of electrolytes * Liver toxicity The use of arsenic trioxide is excluded from the NHS England Treatment Break Policy</p> <p>10. Arsenic trioxide is to be otherwise used as set out in its SPC</p>	From 04-May-18			No	n/a	Yes	Yes	No	11-Sep-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
ARS2_v1.1	Arsenic trioxide	Arsenic trioxide for treating relapsed/refractory acute promyelocytic leukaemia in ADULTS where the following criteria are met:	<p>1. An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. This patient is an ADULT and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene</p> <p>3. The patient has acute promyelocytic leukaemia which is EITHER refractory to or relapsed after previous treatment which included a retinoid and chemotherapy OR has relapsed after a complete remission which lasted at least 2 years following previous arsenic trioxide and all-trans-retinoic acid treatment</p> <p>4. The patient will be treated with induction and consolidation treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA) As combination therapy with ATRA is unlicensed in this relapsed/refractory setting, hospital Trust policy regarding unlicensed treatments should be followed</p> <p>5. Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 50 if the dosing and schedule is used as in the Summary of Product Characteristics or by day 60 if the UK NCRI AML 17 protocol is used (Lancet Oncology 2015; 16: 1295-1305), arsenic trioxide will be discontinued</p> <p>6. As consolidation therapy, either the dosing and schedule in the Summary of Product Characteristics is used for a maximum of 5 weeks or the dosing and scheduling of the UK NCRI AML17 protocol (Lancet Oncology 2015; 16: 1295-1305) is used for a maximum of 4 cycles of arsenic trioxide, each cycle being 4 weeks on treatment followed by 4 weeks off therapy</p> <p>7. The dosing and schedule of administration of arsenic trioxide will be either in accordance with that described in the Summary of Product Characteristics (SPC) or that used in the UK NCRI AML17 protocol. If the AML17 dosing and schedule is used, hospital Trust policy regarding unlicensed treatments should be followed</p> <p>8. The treating team is aware of the risk of and the treatment for * APL differentiation syndrome * QT interval prolongation and the need for monitoring of electrolytes * Liver toxicity Arsenic trioxide is excluded from the NHS England Treatment Break Policy</p> <p>9. That arsenic trioxide is to be otherwise used as set out in its SPC</p>	From 04-May-18	No	n/a	Yes	Yes	No	11-Sep-18		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
ARS3_v1.1	Arsenic trioxide	Arsenic trioxide for treating newly diagnosed low to intermediate risk acute promyelocytic leukaemia in CHILDREN where the following criteria are met:	<ol style="list-style-type: none"> 1. An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The patient is a CHILD and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene 3. The patient is newly diagnosed with acute promyelocytic leukaemia 4. The patient has low to intermediate risk acute promyelocytic leukaemia (white cell count $\leq 10 \times 10^9/L$) and has not received any chemotherapy for this. Patients with high risk acute promyelocytic leukaemia are not funded for treatment with arsenic trioxide 5. The patient will be treated with induction treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA) 6. Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 60, arsenic trioxide will be discontinued 7. As consolidation therapy, a maximum of 4 cycles of arsenic trioxide will be prescribed, each cycle being 4 weeks on treatment followed by 4 weeks off therapy 8. The patient is a pre-pubescent or post-pubescent child and will be treated with the dosing and schedule of administration of arsenic trioxide either in accordance with that described in the Summary of Product Characteristics (SPC) or that used in the UK NCRI AML17 trial as reported in Lancet Oncology 2015; 16: 1295-1305. 9. The use of arsenic trioxide has been discussed at a multi-disciplinary team (MDT) meeting which must include two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area 10. The hospital Trust policy regarding unlicensed treatments has been followed as arsenic trioxide is not licensed in this indication in children 11. The treating team is aware of the risk of and the treatment for <ul style="list-style-type: none"> * APL differentiation syndrome * QT interval prolongation and the need for monitoring of electrolytes * Liver toxicity Arsenic trioxide is excluded from the NHS England Treatment Break Policy 12. Arsenic trioxide is to be otherwise used as set out in its SPC 	From 04-May-18	No	n/a	Yes	Yes	No	11-Sep-18		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
ARS4_v1.1	Arsenic trioxide	Arsenic trioxide for treating relapsed/refractory acute promyelocytic leukaemia in CHILDREN where the following criteria have been met:	<p>1. An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient is a CHILD and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene</p> <p>3. The patient has acute promyelocytic leukaemia which is EITHER refractory to or relapsed after previous treatment which included a retinoid and chemotherapy OR has relapsed after a complete remission which lasted at least 2 years following previous arsenic trioxide and all-trans-retinoic acid treatment</p> <p>4. The patient will be treated with induction and consolidation treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA) As combination therapy with ATRA is unlicensed in this relapsed/refractory setting, hospital Trust policy regarding unlicensed treatments should be followed</p> <p>5. Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 50 if the dosing and schedule is used as in the Summary of Product Characteristics or by day 60 if the UK NCRI AML 17 protocol is used (Lancet Oncology 2015; 16: 1295-1305), arsenic trioxide will be discontinued</p> <p>6. As consolidation therapy, either the dosing and schedule in the Summary of Product Characteristics is used for a maximum of 5 weeks or the dosing and scheduling of the UK NCRI AML17 protocol (Lancet Oncology 2015; 16: 1295-1305) is used for a maximum of 4 cycles of arsenic trioxide, each cycle being 4 weeks on treatment followed by 4 weeks off therapy</p> <p>7. The patient is a pre-pubescent or post-pubescent child and will be treated with the dosing and schedule of administration of arsenic trioxide either in accordance with that described in the Summary of Product Characteristics (SPC) or that used in the UK NCRI AML17 protocol as reported in Lancet Oncology 2015; 16: 1295-1305.</p> <p>8. The use of arsenic trioxide has been discussed at a multi-disciplinary team (MDT) meeting which must include two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area</p> <p>9. The hospital Trust policy regarding unlicensed treatments has been followed as arsenic trioxide is not licensed in this indication in children</p> <p>10. The treating team is aware of the risk of and the treatment for * APL differentiation syndrome * QT interval prolongation and the need for monitoring of electrolytes * Liver toxicity Arsenic trioxide is excluded from the NHS England Treatment Break Policy</p> <p>11. Arsenic trioxide is to be otherwise used as set out in its SPC.</p>	From 04-May-18	No	n/a	Yes	Yes	No	11-Sep-18		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
ATE1_v1.1	Atezolizumab	The first line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin-based chemotherapy where all the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy with atezolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract</p> <p>4. The patient has disease that is either locally advanced (ie T4b any N or any T N2-3 disease) or metastatic (any T any N M1 disease)</p> <p>5. The patient has not received previous chemotherapy for inoperable locally advanced or metastatic urothelial cancer</p> <p>6. The patient has EITHER not received previous adjuvant chemotherapy, neoadjuvant chemotherapy or chemo-radiotherapy OR, if previously treated with platinum-based chemotherapy whether as adjuvant chemotherapy or as neoadjuvant chemotherapy or with chemo-radiotherapy, has relapsed more than 12 months since completing the platinum-based chemotherapy * Patients meeting this criterion are eligible to be considered as treatment naïve for locally advanced/ metastatic disease but must satisfy all other criteria</p> <p>7. The patient has an ECOG performance status (PS) of 0, 1 or 2. Note: treatment of patients of performance status 2 should only proceed with caution as there is limited safety data on PS 2 patients with urothelial cancer treated with atezolizumab.</p> <p>8. The patient is ineligible for platinum-based chemotherapy, due to one or more of the following: * impaired renal function (EDTA-assessed glomerular filtration rate >30 and <60mls/min) * hearing loss of 25dB as assessed by formal audiometry * NCI CTCAE grade 2 or worse peripheral neuropathy * ECOG PS 2</p> <p>9. The patient's urothelial tumour has undergone PD-L1 testing</p> <p>10. A PD-L1 expression of ≥5% has been recorded and the measurement used for PD-L1 testing is defined as the presence of discernible PD-L1 staining of any intensity in tumour infiltrating immune cells covering ≥5% of tumour area occupied by tumour cells, associated intra-tumoural and contiguous peri-tumoural desmoplastic stroma</p> <p>11. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody</p> <p>12. The patient has no symptomatically active brain metastases or leptomeningeal metastases</p> <p>13. Atezolizumab is being given as monotherapy and will commence at a fixed dose of 1200mg every 3 weeks</p> <p>14. A formal medical review as to whether treatment with atezolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment</p> <p>15. The patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner</p> <p>16. Treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle</p> <p>17. Atezolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 01-Nov-17	No	n/a	nca	nca	Yes	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
AVE1_v1.0	Avelumab	The treatment of previously untreated (with systemic therapy) metastatic Merkel cell carcinoma where all the following criteria are met:	<ol style="list-style-type: none"> 1. An application is made by and the first cycle of systemic anti-cancer therapy with avelumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis 3. The patient has a confirmed histological or cytological diagnosis of Merkel cell carcinoma 4. The patient has metastatic disease 5. The patient is treatment naïve to any systemic anti-cancer therapy for Merkel cell carcinoma and in particular has not received any prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4] antibody 6. The patient has an ECOG performance status of either 0 or 1. Note: a patient with a performance status of 2 or more is not eligible for avelumab 7. If the patient has brain metastases, then these have been treated and are stable 8. Avelumab is to be used as monotherapy only 9. Avelumab is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment. I also confirm that patients with radiological disease progression not associated with significant clinical deterioration (defined as no new or worsening symptoms and no change in performance status for greater than 2 weeks and no need for salvage therapy: all 3 conditions must apply) can continue treatment 10. A formal medical review as to whether treatment with avelumab should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment 11. Treatment breaks of up to 12 weeks beyond the expected cycle length of avelumab are allowed but solely to allow immune toxicities to settle 12. Avelumab will otherwise be used as set out in its Summary of Product Characteristics (SPC). 	From 01-Mar-2018			No	n/a	Yes	Agreed	Yes	nca
BEN6_v2.1	Bendamustine	The treatment of relapsed low grade lymphoma where all the following criteria are met:	<ol style="list-style-type: none"> 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Low grade non-Hodgkin's lymphoma 3. Relapsed disease 4. Unable to receive CHOP-R 5. Unable to receive FCR 6. Unable to receive high dose-therapy 7. No prior bendamustine 8. To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication <p>Note: Can be used in combination with Rituximab, which is commissioned by NHS England for this indication.</p>	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
BEN5_v2.1	Bendamustine	The treatment of relapsed multiple myeloma where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Multiple myeloma 3. Relapsed disease where all other treatments contraindicated or inappropriate 4. To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca
BEV2_v1.4	Bevacizumab	The first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy where all the following criteria are met:	1. An application has been made and the first cycle of systemic anti -cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The patient has histologically confirmed carcinoma of the cervix 3. The indication will be for 1st line palliative chemotherapy 4. The patient has primary stage IVB, recurrent, or persistent disease not amenable to curative treatment with surgery and/or radiotherapy 5. Bevacizumab will be given with Paclitaxel and either Cisplatin or Carboplatin 6. The patient has an ECOG PS of 0 or 1 7. The patient has had no previous treatment with bevacizumab or other anti-VEGF therapy 8. The patient has no contraindications to the use of bevacizumab 9. Bevacizumab dose to be 15mg/kg every 3 weeks 10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process Note: Bevacizumab is ONLY approved for use in combination with combination chemotherapy and is not approved for use as a single agent maintenance therapy Note: Bevacizumab should be discontinued for reasons of toxicity or disease progression, whichever occurs first.	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca
BEV8_v1.3	Bevacizumab	The third line treatment of low grade gliomas of childhood where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant paediatric specialist specifically trained and accredited in 2. Progressive low grade glioma 3. No previous treatment with either irinotecan or bevacizumab 4. Irinotecan and bevacizumab to be the 3rd or further line of therapy 5. A maximum of 12 months duration of treatment to be used with a re-application required at 6 months 6. Consent with the parent/guardian to specifically document the unknown long term toxicity of this combination, particularly on growth and ovarian function 7. To be used within the treating Trust's governance framework, as Bevacizumab and Irinotecan are not licensed in this indication in children 8. In the period immediately prior to the application for irinotecan and bevacizumab, the appropriate specialist MDT has considered the use of proton beam radiotherapy. NOTE: Bevacizumab is ONLY approved for use in combination with combination chemotherapy and is not approved for use as a single agent maintenance therapy NOTE: Additional data on long term toxicity must be collected by the paediatric oncology community	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
BEV3_v2.1	Bevacizumab	The first line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Chemotherapy naïve advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (not licensed at this dosage) 3. 1st line indication 4. Patients must satisfy one of the following criteria: i) FIGO stage III debulked but residual disease more than 1cm OR ii) Stage IV disease OR iii) Stage III at presentation and requiring neo-adjuvant chemotherapy due to low likelihood of optimal primary surgical cytoreduction 5. Given with Carboplatin and Paclitaxel combination chemotherapy 6. Bevacizumab to start with: · 1st or 2nd cycle of chemotherapy following primary debulking surgery, OR · 1st or 2nd cycle of chemotherapy following interval debulking surgery performed after 3-4 cycles of neo-adjuvant chemotherapy, OR · 1st or 2nd cycles of chemotherapy for those patients with stage IV disease or inoperable disease, OR · 1st cycle of neo-adjuvant chemotherapy 7. Bevacizumab dose to be 7.5mg/kg every 3 weeks and NOT 15mg/kg every 3 weeks 8. Maximum of 18 cycles of Bevacizumab 9. As this dosage of Bevacizumab is not licensed in ovarian cancer it must be used within the treating Trust's governance framework Note: This policy is NOT for patients with stage I-III disease who have had optimal debulking Note: These criteria also apply to patients entered into the ICON 8b trial. Clinicians should be aware that for patients randomised to the non-bevacizumab arm of ICON 8b, the use of bevacizumab in subsequent lines of treatment is not approved under current CDF criteria.	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca
BOR1_v2.1	Bortezomib	The treatment of bortezomib naïve relapsed multiple myeloma where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Relapsed myeloma 3. No previous Bortezomib	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
BRE5_v1.3	Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option in ADULT patients where the following criteria are met:	<p>1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient is an adult* *note there is a separate blueteq form to be used for brentuximab in this indication in children</p> <p>3. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.</p> <p>4. The patient has relapsed Hodgkin lymphoma after at least 2 prior systemic therapies when either autologous stem cell transplant or further multi-agent chemotherapy is not a treatment option.</p> <p>5. The patient has had no previous stem cell transplant</p> <p>6. The patient has never received brentuximab unless previously enrolled in the NCR1-adopted clinical trial called ECHELON-1</p> <p>7. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</p> <p>8. I confirm that no more than 16 cycles of brentuximab may be administered per patient</p> <p>9. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>10. No re-use of brentuximab will be used outside this indication unless previous partial/complete response to brentuximab and brentuximab is being used as a bridge to allogeneic stem cell transplant or donor lymphocyte infusion* *note there is a separate blueteq form for such re-use of brentuximab</p> <p>11. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 29-Jul-16			Yes	Agreed	Yes	Yes	nca	11-Sep-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
BRE6_v1.2	Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option in CHILd patients where the following criteria are met:	<p>1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002 http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378 *note there is a separate Blueteq form to be used for brentuximab in this indication in adults.</p> <p>3. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.</p> <p>4. The patient has relapsed Hodgkin lymphoma after at least 2 prior systemic therapies when either autologous stem cell transplant or further multi-agent chemotherapy is not a treatment option.</p> <p>5. The patient has had no previous stem cell transplant</p> <p>6. The patient has never received brentuximab</p> <p>7. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</p> <p>8. I confirm that no more than 16 cycles of brentuximab may be administered per patient</p> <p>9. The use of the brentuximab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.</p> <p>10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>11. No re-use of brentuximab will be used outside this indication unless previous partial/complete response to brentuximab and brentuximab is being used as a bridge to allogeneic stem cell transplant or donor lymphocyte infusion* *note there is a separate blueteq form for such re-use of brentuximab</p> <p>12. Trust policy regarding unlicensed treatments has been followed as brentuximab is not licensed in this indication in children.</p> <p>13. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 29-Jul-16			Yes	Agreed	Yes	Agreed	nca	11-Sep-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
CABO3_v1.0	Cabozantinib	The treatment of treatment-naïve intermediate or poor risk advanced renal cell carcinoma where the following criteria are met:	<ol style="list-style-type: none"> 1. Application is made by and the first cycle of systemic anti-cancer therapy with cabozantinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. This patient has a confirmed histological diagnosis of renal cell carcinoma (RCC) with a clear cell component 3. The patient has either metastatic disease or inoperable locally advanced disease 4. The patient is treatment naïve to systemic therapy and in particular has previously received neither any vascular endothelial growth factor (VEGF)-targeted systemic therapy nor mTOR pathway inhibitor-targeted treatment unless prior treatment with pazopanib or sunitinib or tivozanib has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of progressive disease 5. The patient has intermediate risk OR poor risk advanced renal cell carcinoma as defined by the International Metastatic Renal Cell Carcinoma Database Consortium. Good risk patients are not eligible for cabozantinib therapy. Intermediate risk is defined as having 1 or 2 risk factors and poor risk as having ≥3 factors, these factors being: <ul style="list-style-type: none"> - Time from diagnosis of RCC to need for systemic therapy of <1 year - Haemoglobin < lower limit of normal - Corrected calcium > upper limit of normal - Karnofsky performance status <80% - Neutrophils > upper limit of normal - Platelet count > upper limit of normal 6. The patient has an ECOG performance status of either 0 or 1 or 2 7. If the patient has brain metastases, then these have been treated and are stable 8. Cabozantinib is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment 9. A formal medical review as to whether treatment with cabozantinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment 10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process. 11. Cabozantinib is to be otherwise used as set out in its Summary of Product Characteristics 	From 24-Aug-18	No	n/a	Yes	Agreed	No	tbc		
CLO2_v2.0	Clofarabine	The treatment of relapsed/refractory acute myeloblastic leukaemia where all the following criteria are met:	<ol style="list-style-type: none"> 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Acute myeloblastic leukaemia (not licensed for this indication) 3. Relapsed/ refractory disease with intent to use treatment to bridge to bone marrow transplant 4. To be used within the treating Trust's governance framework, as Clofarabine is not licensed for this indication 	From 29-Jul-16	Yes	Agreed	nca	nca	nca	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
CLO1_v2.0	Clofarabine	The treatment of relapsed/refractory acute lymphoblastic leukaemia where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Acute lymphoblastic leukaemia 3. Relapsed/ refractory disease with intent to use treatment to bridge to bone marrow transplant	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca
CRI3_v1.0	Crizotinib	1st or subsequent line systemic therapy for ROS1-positive inoperable locally advanced/metastatic non squamous non-small cell lung cancer	1. I confirm that this application is made by and the first cycle of systemic anti-cancer therapy with crizotinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. I confirm that the patient has a histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer that is either stage IIIB or stage IV 3. I confirm that this non squamous NSCLC carries a confirmed ROS1 gene rearrangement as demonstrated by an accurate and validated assay 4. I confirm that the patient has received no previous ROS1-targeted therapy 5. I confirm that EITHER the patient has received no previous cytotoxic chemotherapy for locally advanced or metastatic non-small cell lung cancer OR has been previously treated with cytotoxic chemotherapy for locally advanced or metastatic disease Note: NHS England has a strong preference for ROS1-positive patients to be treated with crizotinib as 1st line therapy for locally advanced/metastatic NSCLC though recognises that some patients have had to be treated with chemotherapy for urgent clinical reasons before the ROS1 result was known 6. I confirm that crizotinib will be used only as single-agent therapy 7. I confirm that the patient has an ECOG performance status of 0 or 1 or 2 8. I confirm that the patient either has no brain metastases or, if the patient has brain metastases, the patient is symptomatically stable prior to starting crizotinib 9. I confirm that the patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner 10. I confirm that treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle 11. I confirm that crizotinib will be otherwise used as set out in its Summary of Product Characteristics (SPC)	From 31-May-18			No	nca	Yes	Agreed	Yes	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
DAR1_v1.0	Daratumumab	The treating relapsed and refractory multiple myeloma where all the following criteria are met:	<p>1. This application is made by and the first cycle of systemic anti-cancer therapy with daratumumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. The patient has a diagnosis of multiple myeloma.</p> <p>3. The patient has received 3 and no more than 3 prior lines of treatment and that the numbering of these lines of treatment is in accordance with the International Myeloma Workshop Consensus recommendations for the uniform reporting of clinical trials (http://doi.org/10.1182/blood-2010-10-299487 . A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner (eg induction chemotherapy and stem cell transplantation is considered to be 1 line of therapy). A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.</p> <p>Note: The use of daratumumab will be audited to confirm it is being used in accordance with these treatment criteria (particularly in respect of lines of therapy) and non-compliant use will be monitored and followed-up.</p> <p>4. The patient has responded to at least 1 of these 3 lines of treatment.</p> <p>5. In relation to the immediately previous line of systemic therapy, the patient has: documented relapse of disease after, initial response or refractory disease.</p> <p>6. The patient has been previously treated with a proteasome inhibitor.</p> <p>7. The patient has been previously treated with an immunomodulatory agent.</p> <p>8. I have informed the CDF as to whether the patient has been treated with a previous stem cell transplant (SCT) or not:</p> <p>9. The patient is of performance status 0 or 1 or 2</p> <p>10. The patient has had no previous therapy with daratumumab or an anti-CD38 antibody</p> <p>11. Daratumumab is only to be used as a single agent. It is not to be used in combination with other agents</p> <p>12. A formal medical review as to whether treatment with daratumumab should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment</p> <p>13. Daratumumab is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment</p> <p>14. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)</p> <p>15. I confirm that daratumumab will be otherwise used as set out in its Summary of Product Characteristics</p>	From 17-Jan-18	No	nca	Yes	Agreed	Yes	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
DIN1_v1.0	Dinutuximab beta	Dinutuximab beta as part of <u>1st line therapy</u> for high risk neuroblastoma in patients aged 12 months and above and who have both responded to induction chemotherapy and been treated with myeloablative therapy and stem cell transplantation where the following criteria are met:	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti -cancer therapy with dinutuximab beta will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for hypersensitivity reactions, capillary leak syndrome, neuropathic pain, peripheral neuropathy and ocular toxicity 3. The patient is currently aged 12 months or older and has histologically documented neuroblastoma according to the International Neuroblastoma Staging System (INSS) 4. The patient has high risk disease defined as either INSS stage 2, 3 , 4 and 4s with MYCN amplification or INSS stage 4 without MYCN amplification and aged >12 months at diagnosis 5. The patient achieved at least a partial response to induction chemotherapy 6. The patient was treated with myeloablative therapy and stem cell transplantation 7. The patient remains free of disease progression following induction chemotherapy and stem cell transplantation 8. The patient has not received prior treatment with an anti-GD2 antibody antibody unless transitioning from the company's current access scheme for high risk patients and provided that all other treatment criteria listed here are fulfilled 9. Dinutuximab beta is not being given in combination with interleukin-2 10. A formal medical review as to whether treatment with dinutuximab beta should continue or not and at what dose will be scheduled to occur at least by the end of the first cycle of treatment 11. The patient will be treated until disease progression or excessive toxicity or completion of 5 cycles of therapy or patient/parent/guardian (as appropriate) choice to discontinue treatment, whichever is the sooner 12. Treatment breaks of up to 6 weeks beyond the expected cycle length are allowed 13. Dinutuximab beta will otherwise be used as set out in its Summary of Product Characteristics (SPC) 	From 12-Jul-18			No	nca	Yes	Agreed	No	20-Nov-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
DIN2_v1.0	Dinutuximab beta	Dinutuximab beta for the treatment of RELAPSED or REFRACTORY neuroblastoma in patients aged 12 months and above and who have then both responded to intensive induction chemotherapy used to treat high risk 1st line patients and been treated with myeloablative therapy and stem cell transplantation where the following criteria are met:	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti -cancer therapy with dinutuximab beta will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for hypersensitivity reactions, capillary leak syndrome, neuropathic pain, peripheral neuropathy and ocular toxicity 3. The patient is currently aged 12 months or older and has histologically documented neuroblastoma according to the International Neuroblastoma Staging System (INSS) 4. The patient has relapsed or refractory neuroblastoma and has disease that requires intensive induction chemotherapy (similar in type to that used in 1st line induction chemotherapy for high risk disease) and myeloablative chemotherapy and stem cell transplantation 5. The patient achieved at least a partial response to induction chemotherapy 6. The patient was treated with myeloablative therapy and stem cell transplantation 7. The patient remains free of disease progression following induction chemotherapy and stem cell transplantation 8. The patient has not received prior treatment with an anti-GD2 antibody 9. Dinutuximab beta is not being given in combination with interleukin-2 10. A formal medical review as to whether treatment with dinutuximab beta should continue or not and at what dose will be scheduled to occur at least by the end of the first cycle of treatment 11. The patient will be treated until disease progression or excessive toxicity or completion of 5 cycles of therapy or patient/parent/guardian (as appropriate) choice to discontinue treatment, whichever is the sooner 12. Treatment breaks of up to 6 weeks beyond the expected cycle length are allowed 13. Dinutuximab beta will otherwise be used as set out in its Summary of Product Characteristics (SPC) 	From 12-Jul-18			No	nca	Yes	Agreed	No	20-Nov-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
IBR4_v1.1	Ibrutinib	The treatment of Waldenstrom's Macroglobulinaemia where all the following criteria are met:	<p>1. The application has been made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has a confirmed clinicopathological diagnosis of Waldenstrom's Macroglobulinaemia (WM) and meets the consensus panel criteria from the Second International Workshop on WM (Owen RG 2003 - https://www.ncbi.nlm.nih.gov/pubmed/12720135)</p> <p>3. The patient has symptomatic disease meeting at least one of the recommendations for requiring active treatment as set out in the Second International Workshop on WM (Kyle et al 2003 - https://www.ncbi.nlm.nih.gov/pubmed/12720119).</p> <p>4. Presence of documented progression of disease: * After response to previous line of treatment OR * No response to previous line of systemic therapy</p> <p>5. The patient has received at least 1 prior line of treatment</p> <p>6. The patient has received the following previous treatments (please select one or more as relevant): Chlorambucil single agent; Rituximab single agent; Bendamustine single agent; Chlorambucil plus rituximab; Bendamustine plus rituximab; FCR; Cladribine plus rituximab; DRC; Bortezomib combination; Other</p> <p>7. The patient has never received any B cell receptor therapies (ibrutinib, idelalisib, acalabrutinib)</p> <p>8. Ibrutinib is to be used as a single agent</p> <p>9. Ibrutinib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment</p> <p>10. The patient's performance status is 0, 1 or 2</p> <p>11. The patient's neutrophil count is $\geq 1 \times 10^9/L$</p> <p>12. The patient's platelet count $\geq 50 \times 10^9/L$</p> <p>13. The patient is not on concurrent therapy with warfarin or CYP3A4/5 inhibitors</p> <p>14. no treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)</p> <p>15. ibrutinib will be otherwise used as set out in its Summary of Product Characteristics</p>	From 28-Sep-17			No	nca	nca	nca	Yes	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
INO1_v1.0	Inotuzumab ozogamicin	The treatment of relapsed/refractory Philadelphia positive and Philadelphia negative B cell precursor acute lymphoblastic leukaemia in ADULT patients where all the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy with inotuzumab ozogamicin will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The prescribing clinician is fully aware of the risk factors for inotuzumab ozogamicin inducing hepatotoxicity including veno-occlusive liver disease/sinusoidal obstruction syndrome and that this risk rises as the number of cycles administered increases</p> <p>3. The patient has relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Please tick appropriate box as to which type of ALL the patient has: * Philadelphia chromosome negative ALL or * Philadelphia chromosome positive ALL in which case treatment with at least one second or third generation TKI must have also failed</p> <p>4. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage</p> <p>5. The patient is an adult* *note there is a separate Blueteq form to be used for inotuzumab ozogamicin in this</p> <p>6. Inotuzumab ozogamicin will only be requested by and administered in either bone marrow transplant centres or in major haematological centres that regularly treat patients with relapsed/refractory ALL and who have regular ALL multi-disciplinary team meetings and close links with bone marrow transplant centres</p> <p>7. The patient has an ECOG performance status of 0 - 2</p> <p>8. The following treatment duration policy will apply to the use of inotuzumab ozogamicin: for those patients proceeding to a stem cell transplant (SCT), the recommended duration of treatment is 2 cycles. A 3rd cycle may be considered for those patients who do not achieve a complete remission (CR) or a CR with incomplete haematological recovery (CRi) and minimal residual disease negativity after 2 cycles. For patients not proceeding to a SCT, a maximum of 6 cycles of treatment may be administered. Patients who do not achieve a CR or CRi within 3 cycles should discontinue treatment</p> <p>9. Inotuzumab ozogamicin will be used as monotherapy</p> <p>10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*</p> <p>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>11. Inotuzumab ozogamicin will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 09-Aug-2018			No	nca	Yes	Yes	No	tbc

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			Yes	Yes (but notice of removal served)	No						
INO2_v1.0	Inotuzumab ozogamicin	<p>The treatment of relapsed/refractory Philadelphia positive and negative B cell precursor acute lymphoblastic leukaemia in CHILD patients where all the following criteria are met:</p> <ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy with inotuzumab ozogamicin will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The prescribing clinician is fully aware of the risk factors for inotuzumab ozogamicin inducing hepatotoxicity including veno-occlusive liver disease/sinusoidal obstruction syndrome and that this risk rises as the number of cycles administered increases 3. The patient has relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Please tick appropriate box as to which type of ALL the patient has: * Philadelphia chromosome negative ALL or * Philadelphia chromosome positive ALL in which case treatment with at least one second or third generation TKI must have also failed 4. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage chemotherapy or blinatumomab 5. The patient is a child* and: - is post pubescent or - is pre-pubescent and will receive inotuzumab ozogamicin at the dosage described in the results of the inotuzumab ozogamicin trial in children and reported in Pediatric Blood Cancer 2014; 61: 369-372 doi: 10.1002/pcb.24721 *note there is a separate Blueteq form to be used for inotuzumab ozogamicin in this indication in adults. 6. Inotuzumab ozogamicin will only be requested by and administered in principal treatment centres 7. The use of the inotuzumab ozogamicin has been discussed at a multi-disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area 8. The patient has a performance status of 0 - 2 9. The following treatment duration policy will apply to the use of inotuzumab ozogamicin: for those patients proceeding to a stem cell transplant (SCT), the recommended duration of treatment is 2 cycles. A 3rd cycle may be considered for those patients who do not achieve a complete remission (CR) or a CR with incomplete haematological recovery (CRi) and minimal residual disease negativity after 2 cycles. For patients not proceeding to a SCT, a maximum of 6 cycles of treatment may be administered. Patients who do not achieve a CR or CRi within 3 cycles should discontinue treatment 10. Inotuzumab ozogamicin will be used as monotherapy 11. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process 12. Trust policy regarding unlicensed treatments has been followed as inotuzumab ozogamicin is not licensed in this indication in children 13. Inotuzumab ozogamicin will otherwise be used as set out in its Summary of Product Characteristics (SPC). 	From 09-Aug-2018			No	nca	Yes	Yes	No	tbc

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			Yes	Yes (but notice of removal served)	No						
IXA1_v1.1	Ixazomib with lenalidomide and dexamethasone	<p>The treatment of relapsed or refractory multiple myeloma where all the following criteria are met:</p> <ol style="list-style-type: none"> 1. The application was made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. The patient has a confirmed diagnosis of multiple myeloma. 3. I confirm that the patient has received 2 or 3 prior lines of treatment and that the numbering of these lines of treatment is in accordance with the International Myeloma Workshop Consensus recommendations for the uniform reporting of clinical trials (http://doi.org/10.1182/blood-2010-10-299487). A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner (eg induction chemotherapy and stem cell transplantation is considered to be 1 line of therapy). A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease. Please indicate the number of prior lines of treatment: Note: The use of ixazomib will be audited to confirm it is being used in accordance with these treatment criteria (particularly in respect of lines of therapy) and non-compliant use will be monitored and followed-up. Note: Patients previously treated with 1 or >3 lines of treatment are not eligible for ixazomib. 4. The patient is neither refractory to previous proteasome inhibitor-based nor lenalidomide-based treatment at any line of therapy (in this context, refractory disease is defined as disease progression on treatment or disease progression within 60 days of the last dose of a proteasome inhibitor or lenalidomide). Note: As lenalidomide is only commissioned by NHS England after 2 prior therapies, the only eligible patients who have had prior lenalidomide must have received it in the context of a clinical trial in an earlier line of therapy. Such patients must not be refractory to lenalidomide according to the above definition. 5. The patient has either been refractory to 1 or more lines of therapy or has responded and relapsed after each line of therapy. 6. Please indicated whether the patient has / has not been treated with a previous autologous or allogenic stem cell transplant. 7. The patient must be treatment-naïve to any therapy with ixazomib 8. Ixazomib is only to be used in combination with lenalidomide and dexamethasone* <p>*Note: all 3 drugs in the combination (i.e. ixazomib, lenalidomide and dexamethasone) must be commenced at the same time. Ixazomib cannot be added in as an additional agent in the treatment of patients who have already previously commenced treatment with lenalidomide and dexamethasone.</p> <ol style="list-style-type: none"> 9. Ixazomib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment, whichever is the sooner 10. Performance status of the patients is 0 or 1 or 2 11. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve) 12. Ixazomib to be otherwise used as set out in its Summary of Product Characteristics 	From 19-Dec-17	No	nca	Yes	Yes	Yes	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
LNV2_v1.0	Lenvatinib	The treatment of differentiated thyroid cancer after radioactive iodine where all the following criteria are met:	<p>1. This application is made by and the first cycle of systemic anti-cancer therapy with lenvatinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. This patient has a confirmed histological diagnosis of differentiated thyroid carcinoma (papillary or follicular or Hurtle cell type)</p> <p>3. The patient has either metastatic disease or inoperable locally advanced disease</p> <p>4. The disease is refractory to radioactive iodine</p> <p>5. The disease is progressive and is either symptomatic or imminently likely to become symptomatic</p> <p>6. The patient is treatment naïve to both lenvatinib and sorafenib unless either: a) previously enrolled in the company's lenvatinib compassionate access scheme and all other NHS England treatment criteria are fulfilled ie if treated with previous sorafenib, lenvatinib will only be accepted for NHS funding if the patient was intolerant of sorafenib according to the conditions set out in b) below or b) the patient has had to discontinue sorafenib within 3 months of starting sorafenib because of toxicity (ie there is sorafenib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on sorafenib</p> <p>Note: Sequential use of lenvatinib and then sorafenib is only funded if the patient has to discontinue lenvatinib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on lenvatinib. The use of lenvatinib after disease progression on or after sorafenib is not funded and vice versa.</p> <p>7. The patient has an ECOG performance status of 0 or 1 or 2</p> <p>8. Lenvatinib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment</p> <p>9. A formal medical review as to whether treatment with lenvatinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment</p> <p>10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)</p> <p>11. Lenvatinib is to be otherwise used as set out in its Summary of Product Characteristics</p>	From 15-Feb-18			No	nca	Yes	Agreed	No	06-Nov-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
LUT1_v1.0	Lutetium oxodotreotide	Lutetium oxodotreotide for unresectable or metastatic, progressive, well differentiated and somatostatin receptor positive gastroenteropancreatic neuroendocrine carcinoma where all the following criteria are met:	<p>1. This application is made by a consultant oncologist who is specifically trained and accredited in the use of systemic anti-cancer therapy and who is a core member of the relevant Neuroendocrine Carcinoma Multi-Disciplinary Team (MDT)</p> <p>2. The Neuroendocrine Carcinoma MDT has confirmed the arrangements by which only persons authorised to handle radiopharmaceuticals (such as lutetium oxodotreotide) do so in authorised clinical settings and after evaluation of the patient by an appropriately trained and accredited physician</p> <p>3. The patient has a histologically documented, well differentiated neuroendocrine carcinoma of the gastrointestinal tract or pancreas</p> <p>Note: patients with primary bronchial neuroendocrine carcinomas are not eligible for treatment with lutetium oxodotreotide</p> <p>4. The patient's disease is either unresectable or metastatic</p> <p>5. The patient's disease is somatostatin receptor positive on imaging (on PET scanning but otherwise on scintigraphy if PET scanning not possible) and this imaging confirms overexpression of somatostatin receptors in the tumour tissue with the tumour uptake at least as high as normal liver uptake (tumour uptake grade score ≥ 2)</p> <p>6. There has been recent demonstration in this patient of disease progression on CT or MR imaging over the course of a maximum period of 3 years</p> <p>7. The patient has an ECOG performance status (PS) score of 0 or 1 or 2</p> <p>8. The patient has not received prior treatment with lutetium oxodotreotide</p> <p>Note: re-treatment with a further program of lutetium oxodotreotide treatments is not commissioned</p> <p>9. Lutetium oxodotreotide is being given as monotherapy (bar somatostatin analogues in between treatments) and will involve a maximum of 4 infusions of 7400 MBq as long as there is no evidence of disease progression</p> <p>10. A formal face to face medical review as to whether treatment with lutetium oxodotreotide should continue or not will be scheduled to occur before each of the 4 planned treatment administrations</p> <p>11. The prescribing clinician notes that the use of lutetium oxodotreotide is exempt from the NHS England cancer drug Treatment Breaks policy</p> <p>12. Lutetium oxodotreotide will otherwise be used as set out in its Summary of Product Characteristics (SPC)</p>	From 20-Jul-18			No	n/a	Yes	Agreed	No	27/11/2018

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
MID1_v1.1	Midostaurin	Midostaurin for treating FLT3 mutation positive acute myeloid leukaemia in adults where the following criteria are met:	<ol style="list-style-type: none"> 1. An application is made by and the first cycle of systemic anti-cancer therapy with midostaurin will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The patient is an adult and has a confirmed diagnosis of acute myeloid leukaemia 3. The patient has a FLT3 mutation as determined by a validated test 4. The patient is newly diagnosed with FLT3 positive acute myeloid leukaemia and has not received any chemotherapy for this 5. The patient is fit for intensive induction chemotherapy 6. The patient will be treated with midostaurin in combination with standard daunorubicin and cytarabine induction chemotherapy and in combination with high dose cytarabine consolidation chemotherapy Midostaurin is excluded from the NHS England Treatment Breaks Policy. 7. As maintenance monotherapy, midostaurin is to be only used in patients in complete remission of their AML 8. In the maintenance monotherapy phase, a maximum of 12 28-day cycles of midostaurin will be used 9. If the patient proceeds to a stem cell transplant, midostaurin will be permanently discontinued prior to the stem cell transplant conditioning regimen 10. Midostaurin is to be otherwise used as set out in its Summary of Product Characteristics 	From 04-May-18			No	n/a	Yes	Agreed	No	11-Sep-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
NIR1_v1.0	Niraparib	Niraparib as maintenance treatment in patients with relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND line chemotherapy and who HAVE a germline BRCA mutation where the following criteria are met:	<ol style="list-style-type: none"> 1. This application is made by and the first cycle of systemic anti-cancer therapy with niraparib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The prescribing clinicians is fully aware of the likely toxicities of niraparib, the associated monitoring required and the reasons why 48% of patients in the ENGOT-OV16/NOVA trial had dose interruptions in the 1st cycle and 47% commenced their 2nd cycle at a reduced niraparib dosage 3. The patient has a confirmed histological diagnosis of predominantly high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma 4. The patient has had a germline BRCA test 5. The patient HAS a documented germline BRCA mutation 6. The patient relapsed following 1st line chemotherapy (ie the penultimate line of treatment) and had platinum-sensitive disease at this relapse, platinum sensitivity defined by a complete or partial remission which lasted for more than 6 months following completion of 1st line platinum-based chemotherapy (whether given pre-and/or post-operatively or if the patient did not have surgery) 7. The patient is in a complete or partial response following completion of 2nd line platinum-based chemotherapy (ie the most recent chemotherapy) and that the serum CA125 is either normal or has demonstrated a >90% decrease from before the initiation of 2nd line chemotherapy and is stable 8. The patient is less than 12 weeks since completing 2nd line chemotherapy 9. The patient has not previously received any PARP inhibitor 10. The patient has an ECOG performance status of either 0 or 1. A patient with a performance status of 2 or more is not eligible for niraparib 11. Niraparib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment 12. A formal medical review as to whether maintenance treatment with niraparib should continue or not and at what dose will be scheduled to occur at least by the start of the second cycle of treatment 13. Niraparib will be used as monotherapy 14. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve) 15. Niraparib is to be otherwise used as set out in its Summary of Product Characteristics 	From 01-Jun-18	No	nca	Yes	Agreed	Yes	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
NIR2_v1.0	Niraparib	Niraparib as maintenance treatment in patients with relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND OR LATER line chemotherapy and who DO NOT HAVE a germline BRCA mutation where the following criteria are met:	<ol style="list-style-type: none"> 1. This application is made by and the first cycle of systemic anti-cancer therapy with niraparib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The prescribing clinician is fully aware of the likely toxicities of niraparib, the associated monitoring required and the reasons why 48% of patients in the ENGOT-OV16/NOVA trial had dose interruptions in the 1st cycle and 47% commenced their 2nd cycle at a reduced niraparib dosage 3. The patient has a confirmed histological diagnosis of predominantly high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma 4. The patient has had a germline BRCA test 5. The patient DOES NOT HAVE a documented germline BRCA mutation 6. The patient relapsed following the penultimate line of chemotherapy (ie the line of treatment preceding the most recent line of chemotherapy) and had platinum-sensitive disease at this relapse, platinum sensitivity defined by a complete or partial remission which lasted for more than 6 months following completion of this penultimate line of platinum-based chemotherapy 7. The patient is in a complete or partial response following completion of the most recent line platinum-based chemotherapy which must be at least second line treatment and that the serum CA125 is either normal or has demonstrated a >90% decrease from before the initiation of this most recent line of chemotherapy and is stable Note: Please state on the form what line of treatment was the most recent line of treatment 8. The patient is less than 12 weeks since completing the most recent line of chemotherapy 9. The patient has not previously received any PARP inhibitor 10. The patient has an ECOG performance status of either 0 or 1. A patient with a performance status of 2 or more is not eligible for niraparib 11. Niraparib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment 12. A formal medical review as to whether maintenance treatment with niraparib should continue or not and at what dose will be scheduled to occur at least by the start of the second cycle of treatment 13. Niraparib will be used as monotherapy 14. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve) 15. Niraparib is to be otherwise used as set out in its Summary of Product Characteristics 	From 01-Jun-18			No	nca	Yes	Agreed	Yes	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
NIV4_v1.0	Nivolumab	The treatment of previously treated locally advanced or metastatic non-squamous non-small cell lung cancer	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has a confirmed diagnosis of stage IIIB or IV non-squamous non-small cell lung cancer</p> <p>3. The patient has progressed after previously receiving at least 2 cycles of platinum-containing chemotherapy for stage IIIB or IV non-small cell lung cancer and also a targeted treatment if the tumour is EGFR positive or ALK positive</p> <p>5. The patient has an ECOG performance status of 0 or 1 and would otherwise be potentially fit for docetaxel-based 2nd line chemotherapy.</p> <p>5. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the nivolumab EAMS programme for this indication and the patient meets all other criteria listed here</p> <p>6. The patient has had PD-L1 testing with an approved and validated test to determine the Tumour Proportion Score.</p> <p>7. The patient's tumour expresses PD-L1 (that is, with a tumour proportion score (TPS) \geq 1%) by an approved and validated test.</p> <p>8. The patient's tumour proportion score* (TPS) is:</p> <p>* Note: the patient's TPS must be provided, otherwise the application will not be authorised.</p> <p>9. Nivolumab will be administered as monotherapy.</p> <p>10. The patient has no symptomatically active brain metastases or leptomeningeal metastases.</p> <p>11. Nivolumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first.</p> <p>*Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until further disease progression is confirmed.</p> <p>12. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) with the exception of criterion 11.</p>	From 20-Sept-17			No	nca	nca	nca	Yes	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
NIV5_v1.0	Nivolumab	The treatment of previously treated locally advanced or metastatic squamous non-small cell lung cancer	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. As the prescribing clinician I am fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. The patient has a histologically or cytologically confirmed diagnosis of stage IIIB or IV squamous non-small cell lung cancer.</p> <p>4. The patient has progressed after previously receiving at least 2 cycles of platinum-containing chemotherapy for stage IIIB or IV non-small cell lung cancer and also a targeted treatment if the tumour is EGFR positive or ALK positive.</p> <p>5. The patient has an ECOG performance status of 0 or 1 and would otherwise be potentially fit for docetaxel-based 2nd line chemotherapy.</p> <p>6. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the nivolumab EAMS programme for this indication and the patient meets all other criteria listed here.</p> <p>7. Every effort has been made for the patient to have PD-L1 testing with an approved and validated test to determine the Tumour Proportion Score (TPS). Please document the TPS results below: - TPS (if negative enter zero): OR - Please enter 'yes', if the TPS cannot be quantified OR - Please enter 'yes', if PD-L1 testing was not possible as the pathologist has documented that these was insufficient tissue</p> <p>8. Nivolumab will be administered as monotherapy.</p> <p>9. The patient has no symptomatically active brain metastases or leptomeningeal metastases.</p> <p>10. Nivolumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first.</p> <p>*Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until further disease progression is confirmed.</p> <p>11. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) with the exception of criterion 10.</p>	From 20-Sept-17			No	nca	nca	nca	Yes	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
NIV6_v1.0	Nivolumab	The treatment of recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy where all the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. As the prescribing clinician I am fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. The patient has a histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck.</p> <p>4. The patient has recurrent or metastatic head and neck cancer that is not amenable to local therapy with curative intent (surgery and/or radiation therapy with or without chemotherapy)</p> <p>5. The patient's disease has progressed or recurred during or within 6 months of the last dose of previously received platinum-based chemotherapy. Please indicate whether this previous platinum-based chemotherapy was given as: adjuvant chemotherapy; neo-adjuvant chemotherapy; concurrent with radiotherapy; or palliative chemotherapy for recurrent or metastatic disease. Note: Patients progressing more than 6 months after completing platinum-based chemotherapy are not eligible for nivolumab.</p> <p>6. The patient has an ECOG performance status of 0 or 1 and would otherwise be potentially fit for docetaxel-based or methotrexate-based 2nd line chemotherapy.</p> <p>7. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.</p> <p>8. Every effort has been made for the patient to have PD-L1 testing with an approved and validated test to determine the Tumour Proportion Score (TPS). Please document the TPS results below: - TPS (if negative enter zero): OR - Please enter 'yes', if the TPS cannot be quantified OR - Please enter 'yes', if PD-L1 testing was not possible as the pathologist has documented that these was insufficient tissue</p> <p>9. Nivolumab will be administered as monotherapy.</p> <p>10. The patient has no symptomatically active brain metastases or leptomeningeal metastases.</p> <p>11. Nivolumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first. *Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until further disease progression is confirmed.</p> <p>12. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) with the exception of criterion 11.</p>	From 13-Oct-17	No	nca	nca	nca	Yes	nca		
NEL1_v2.0	Nelarabine	The treatment of refractory T-cell acute lymphoblastic leukaemia or refractory T-cell lymphoblastic non-Hodgkin's lymphoma where all the following criteria are met:	<p>1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. a) Refractory T-cell acute lymphoblastic leukaemia, OR b) Refractory T-cell lymphoblastic non-Hodgkin's lymphoma</p> <p>3. Treatment intent is to proceed to bone marrow transplantation</p>	From 29-Jul-16	Yes	Agreed	nca	nca	nca	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
OBIBEN1_v1.0	Obinutuzumab with bendamustine	The treatment of follicular lymphoma refractory to rituximab where the following criteria apply:	<p>1. An application has been made by and the first cycle of systemic anti -cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. The patient has a confirmed histological diagnosis of follicular lymphoma.</p> <p>3. The patient has been previously treated for follicular lymphoma with rituximab-containing chemotherapy (i.e. with induction rituximab-containing chemotherapy followed if appropriate by maintenance rituximab therapy).</p> <p>4. The patient has not previously received treatment with bendamustine unless completed more than 2 years previously.</p> <p>5. A maximum of 6 cycles of the combination of obinutuzumab plus bendamustine should be used and followed in responding patients or in those with stable disease with maintenance single agent obinutuzumab once every 2 months for a maximum of 2 years or until disease progression (whichever occurs first).</p> <p>6a. The patient has either failed to respond to or progressed during rituximab-containing combination induction chemotherapy, OR</p> <p>6b. The patient has progressed during or within 6 months of completing maintenance single agent rituximab - please indicate how many months since completion of previous induction rituximab-containing combination chemotherapy progression occurred.</p> <p>7. The patient has an ECOG performance status (PS) of 0 - 2.</p> <p>8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).</p> <p>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process.</p> <p>9. The licensed doses and frequencies of obinutuzumab and bendamustine will be used.</p>	from 27-Jul-17			No	Agreed	nca	nca	Yes	nca

National Cancer Drugs Fund (CDF) List

Bluteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
OLA1_v1.0	Olaratumab	In combination with doxorubicin for the treatment of advanced soft tissue sarcoma in ADULT patients where the following criteria apply:	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The patient has histologically proven soft tissue sarcoma. 3. The patient has locally advanced or metastatic disease. 4. The patient is an adult* *note there is a separate Bluteq form to be used for olaratumab in this indication in children. 5. Treatment intent is palliative ie disease not amenable to potentially curative treatment with surgery and/or radiotherapy. 6. The patient has had no previous treatment with doxorubicin. 7. Olaratumab will be administered in combination with doxorubicin 75mg/m². 8. A maximum of 6 cycles of doxorubicin will be given. 9. Olaratumab will be administered until disease progression/ unacceptable toxicity 10. Olaratumab when given concurrently with chemotherapy will only be used in combination with doxorubicin (ie not with a doxorubicin-containing combination or non-doxorubicin containing regimen) 11. The patient has an ECOG performance status (PS) 0 or 1. 12. The patient has either not received previous adjuvant or neoadjuvant chemotherapy or has but this was not with any doxorubicin-containing regimen. 13. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process 14. Olaratumab will otherwise be used as set out in its Summary of Product Characteristics (SPC). 	From 09-Jun-17			No	n/a	Yes	Agreed	Yes	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
OLA2_v1.1	Olaratumab	In combination with doxorubicin for the treatment of advanced soft tissue sarcoma in PAEDIATRIC patients where the following criteria apply:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has histologically proven soft tissue sarcoma.</p> <p>3. The patient has locally advanced or metastatic disease.</p> <p>4. The patient is a post pubescent child*. *note there is a separate Blueteq form to be used for olaratumab in this indication in adults.</p> <p>5. Olaratumab will only be requested by and administered in principal treatment centres.</p> <p>6. The use of the olaratumab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.</p> <p>7. Treatment intent is palliative ie disease not amenable to potentially curative treatment with surgery and/or radiotherapy.</p> <p>8. The patient has had no previous treatment with doxorubicin.</p> <p>9. Olaratumab will be administered in combination with doxorubicin 75mg/m².</p> <p>10. A maximum of 6 cycles of doxorubicin will be given.</p> <p>11. Olaratumab will be administered until disease progression/unacceptable toxicity</p> <p>12. Olaratumab when given concurrently with chemotherapy is only to be used in combination with doxorubicin (ie not with a doxorubicin-containing combination or non-doxorubicin containing regimen)</p> <p>13. The patient has an ECOG performance status (PS) 0 or 1.</p> <p>14. The patient has either not received previous adjuvant or neoadjuvant chemotherapy or has but this was not with any doxorubicin-containing regimen.</p> <p>15. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*</p> <p>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>16. Trust policy regarding unlicensed treatments should be followed as olaratumab is not licensed in this indication in children</p> <p>17. Olaratumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 09-Jun-17	No	n/a	Yes	Agreed	n/a	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
OSI1_v1.0	Osimertinib	The treatment of locally advanced or metastatic epidermal growth factor receptor and T790M mutation-positive non-small-cell lung cancer (NSCLC) where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Histologically or cytologically documented NSCLC that carries an EGFR and a T790M mutation 3. Locally advanced or metastatic NSCLC 4. Radiological documentation of disease progression following 1st line EGFR TKI treatment with only one TKI and without any further systemic anti-cancer treatment. 5. Treatment with no more than one prior line of treatment for advanced NSCLC 6. No prior chemotherapy unless any prior neoadjuvant or adjuvant chemotherapy had been completed at least 6 months prior to starting 1st line EGFR treatment 7. ECOG PS 0 or 1 8. At time of starting osimertinib, the patient must be fit enough to have potentially started platinum-based doublet chemotherapy	From 04-Oct-16			No	n/a	nca	nca	Yes	nca
PLD1_v2.2	Pegylated Liposomal Doxorubicin	The treatment of sarcomas where all the following criteria are met:	1. An application has been made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. a) Sarcoma in patients with cardiac impairment requiring an anthracycline, 1st line indication, OR b) Sarcoma in patients with cardiac impairment requiring an anthracycline, 2nd line indication 3. To be used within the treating Trust's governance framework, as Pegylated Liposomal Doxorubicin is not licensed in these indications	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
PEMB2_v1.1	Pembrolizumab	The treatment of untreated PD-L1 positive metastatic non-small-cell lung cancer where all the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. The patient has a histologically- or cytologically-confirmed diagnosis of stage IIIB or IV non-small cell lung cancer (squamous or non-squamous)</p> <p>4. The patient's tumour expresses PD-L1 (that is, with a tumour proportion score [TPS] $\geq 50\%$) by an approved and validated test</p> <p>5. The patient either does not have an adenocarcinoma/non-squamous histology OR does have an adenocarcinoma/non-squamous histology but does not have an EGFR or ALK-positive tumour</p> <p>6. The patient has not received previous systemic therapy for advanced /metastatic disease. Completion of treatment with CT and/or RT as part of neoadj/adj therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease</p> <p>7. The patient has an ECOG performance status (PS) of 0 or 1 and is potentially fit for platinum-based chemotherapy</p> <p>8. The patient has no active brain metastases or leptomeningeal metastases</p> <p>9. Pembrolizumab will be administered as monotherapy</p> <p>10. The patient has not received prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless received as part of the pembrolizumab EAMS programme for this indication and meeting all other criteria listed.</p> <p>11. Pembrolizumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first. *Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until further disease progression is confirmed.</p> <p>12. Pembrolizumab will be used as outlined in the Summary of Product Characteristics (SPC) with the exception of criteria 11</p>	From 31-May-17			No	n/a	Yes	Agreed	Yes	16-Oct-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
PEMB3_v1.0	Pembrolizumab	The treatment of locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy with pembrolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis</p> <p>3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract</p> <p>4. The patient's disease is either locally advanced (ie T4b any N or any T N2-3 disease) or metastatic (any T any N M1 disease)</p> <p>5. There has been disease progression during or following previous platinum-based combination chemotherapy for inoperable locally advanced or metastatic urothelial cancer</p> <p>6. The patient has either: not received previous adjuvant chemotherapy, neoadjuvant chemotherapy or chemo-radiotherapy, or if previously treated with platinum-based chemotherapy whether as adjuvant chemotherapy or as neoadjuvant chemotherapy or with chemo-radiotherapy, has relapsed <= 12 months since completing the platinum-based chemotherapy*</p> <p>* Patients meeting this criterion are eligible to be considered as previously treated for locally advanced/ metastatic disease but must satisfy all other criteria</p> <p>7. The patient has an ECOG performance status (PS) score of 0 or 1 or 2 Note: treatment of patients with performance status 2 should only proceed with caution as there is limited safety data on PS 2 patients with urothelial carcinoma treated with pembrolizumab</p> <p>8. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PDL2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the pembrolizumab compassionate use programme for this indication and the patient meets all other criteria listed here</p> <p>9. Pembrolizumab is being given as monotherapy and will commence at a fixed dose of 200mg per infusion</p> <p>10. A formal medical review as to whether treatment with pembrolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment</p> <p>11. The patient is to be treated until disease progression and loss of clinical benefit or excessive toxicity or patient choice, whichever is the sooner</p> <p>12. The patient will receive a maximum treatment duration of 2 years</p> <p>13. Treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle</p> <p>14. The patient has no symptomatically active brain metastases or leptomeningeal metastases</p> <p>15. Pembrolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC)</p>	From 16-Mar-18	Yes	No	No	n/a	Yes	Agreed	Yes	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
PEMB4_v1.0	Pembrolizumab	The treatment of first line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin-based chemotherapy	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy with pembrolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract</p> <p>4. The patient has disease that is either locally advanced (ie T4b any N or any T N2-3 disease) or metastatic (any T any N M1 disease)</p> <p>5. The patient has not received previous chemotherapy for inoperable locally advanced or metastatic urothelial cancer</p> <p>6. The patient has EITHER not received previous adjuvant chemotherapy, neoadjuvant chemotherapy or chemo-radiotherapy for localised urothelial cancer OR, if previously treated with platinum-based chemotherapy whether as adjuvant chemotherapy or as neoadjuvant chemotherapy or with chemo-radiotherapy for localised urothelial cancer, has relapsed more than 12 months since completing the platinum-based chemotherapy* * Patients meeting this criterion are eligible to be considered as treatment naïve for locally advanced/ metastatic disease but must satisfy all other criteria</p> <p>7. The patient has an ECOG performance status (PS) of 0, 1 or 2 Note: treatment of patients with performance status 2 with pembrolizumab should only proceed with caution as there is limited safety data on PS 2 patients with urothelial carcinoma treated with pembrolizumab</p> <p>8. The patient is ineligible for platinum-based chemotherapy, due to one or more of the following: * impaired renal function (EDTA-assessed glomerular filtration rate >30 and <60mls/min) * hearing loss of 25dB or more as assessed by formal audiometry * NCI CTCAE grade 2 or worse peripheral neuropathy * ECOG PS 2</p> <p>9. The patient's tumour has undergone PD-L1 testing</p> <p>10. A PD-L1 expression with a combined positive score (CPS) of ≥10% has been recorded and the CPS is defined as ≥10% of tumour cells and mononuclear inflammatory cells within tumour nests and adjacent supporting stroma expressing PD-L1 at any intensity. The CPS is thus the addition of the numbers of positive tumour and mononuclear inflammatory cells and then this sum is divided by the number of all tumour cells, the result being expressed as a percentage (the maximum of which is set at 100%).</p> <p>11. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the pembrolizumab compassionate access scheme for this indication and the patient meets all other criteria listed here</p> <p>12. The patient has no symptomatically active brain metastases or leptomeningeal metastases</p> <p>13. Pembrolizumab is being given as monotherapy and will commence at a fixed dose of 200mg per infusion</p> <p>14. A formal medical review as to whether treatment with pembrolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment</p> <p>15. The patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner</p> <p>16. The patient will receive a maximum treatment duration with pembrolizumab of 2 years</p> <p>17. Treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle</p> <p>18. Pembrolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 27-Apr-18	No	n/a	Yes	Agreed	Yes	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
PEMB5_v1.0	Pembrolizumab	The treatment of relapsed or refractory classical Hodgkin lymphoma in ADULTS who are stem cell transplant-ineligible and have failed brentuximab vedotin	<p>1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy with pembrolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. I confirm that as the prescribing clinician I am fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. I confirm that the patient is an ADULT and has histologically documented classical Hodgkin lymphoma</p> <p>Note: there is a separate Blueteq form to be used for pembrolizumab in this indication in children</p> <p>4. I confirm that the patient has failed at least 2 lines of chemotherapy and also treatment with brentuximab vedotin</p> <p>5. I confirm that the patient has not received stem cell transplantation of any kind</p> <p>6. I confirm that the patient is currently ineligible for stem cell transplantation</p> <p>7. I confirm that the patient is EITHER a candidate for future stem cell transplantation if there is sufficient benefit of treatment with pembrolizumab OR is not a candidate for stem cell transplantation however good the response to pembrolizumab may be.</p> <p>8. I confirm that the patient has an ECOG performance status (PS) of 0 or 1</p> <p>9. I confirm that the patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody</p> <p>10. I confirm that pembrolizumab is being given as monotherapy and will commence at a fixed dose of 200mg per infusion</p> <p>11. I confirm that a formal medical review as to whether treatment with pembrolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment</p> <p>12. I confirm that the patient will be treated until stem cell transplantation occurs or loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner</p> <p>13. I confirm that the patient will receive a maximum treatment duration with pembrolizumab of 2 years</p> <p>14. I confirm that treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle</p> <p>15. I confirm that pembrolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 25-Jul-18	No	n/a	Yes	Agreed	Yes	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
PEMB6_v1.0	Pembrolizumab	The treatment of relapsed or refractory classical Hodgkin lymphoma in CHILDREN who are stem cell transplant-ineligible and have failed brentuximab vedotin	<p>1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy with pembrolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. I confirm that as the prescribing clinician I am fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. I confirm that the patient is a CHILD and has histologically documented classical Hodgkin lymphoma</p> <p>Note: there is a separate Blueteq form to be used for pembrolizumab in this indication in adults.</p> <p>4. I confirm that the patient has failed at least 2 lines of chemotherapy and also treatment with brentuximab vedotin</p> <p>5. I confirm that the patient has not received stem cell transplantation of any kind</p> <p>6. I confirm that the patient is currently ineligible for stem cell transplantation</p> <p>7. I confirm that the patient is <u>EITHER</u> a candidate for future stem cell transplantation if there is sufficient benefit of treatment with pembrolizumab <u>OR</u> is not a candidate for stem cell transplantation however good the response to pembrolizumab may be</p> <p>9. I confirm that the patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody</p> <p>10. I confirm that pembrolizumab is to be given as monotherapy</p> <p>11. I confirm that the patient is a pre-pubescent or post-pubescent child and will be treated with the 2mg/Kg dosing (maximum dose 200mg) and 3-weekly schedule of pembrolizumab as used in the clinical trial NCT03407144</p> <p>12. I confirm that the use of pembrolizumab has been discussed at a multi-disciplinary team (MDT) meeting which must include 2 consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area</p> <p>13. The hospital Trust policy regarding unlicensed treatments has been followed as pembrolizumab is not licensed in this indication in children</p> <p>14. I confirm that a formal medical review as to whether treatment with pembrolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment</p> <p>15. I confirm that the patient will be treated until stem cell transplantation occurs or loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner</p> <p>16. I confirm that the patient will receive a maximum treatment duration with pembrolizumab of 2 years</p> <p>17. I confirm that treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle</p> <p>18. I confirm that pembrolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	From 25-Jul-18	No	n/a	Yes	Agreed	Yes	nca		

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
SOR2_v3.0	Sorafenib	The treatment of differentiated thyroid cancer after radioactive iodine where the following criteria are met:	<p>1. This application is made by and the first cycle of systemic anti-cancer therapy with sorafenib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. This patient has a confirmed histological diagnosis of differentiated thyroid carcinoma (papillary or follicular or Hurtle cell type)</p> <p>3. The patient has either metastatic disease or inoperable locally advanced disease</p> <p>4. The disease is refractory to radioactive iodine</p> <p>5. The disease is progressive and is either symptomatic or imminently likely to become symptomatic</p> <p>6. The patient is treatment naïve to both lenvatinib and sorafenib unless the patient has had to discontinue lenvatinib within 3 months of starting lenvatinib because of toxicity (ie there is lenvatinib toxicity which cannot be managed by dose delay or dose modification) <u>and</u> there has been no disease progression whilst on lenvatinib</p> <p>Note: Sequential use of sorafenib and then lenvatinib is only funded if the patient has to discontinue sorafenib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on sorafenib. The use of sorafenib after disease progression on or after lenvatinib is not funded and vice versa.</p> <p>7. The patient has an ECOG performance status of 0 or 1 or 2.</p> <p>8. Sorafenib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment</p> <p>9. A formal medical review as to whether treatment with sorafenib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment</p> <p>10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)</p> <p>11. Sorafenib is to be otherwise used as set out in its Summary of Product Characteristics</p>	From 29-Jul-16			Yes	Agreed	Yes	Agreed	nca	06-Nov-18

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
VAN1_v2.3	Vandetanib	The first line treatment of medullary thyroid cancer where all the following criteria are met:	<p>1. This application is made by and the first cycle of systemic anti-cancer therapy with vandetanib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. This patient has a confirmed histological diagnosis of medullary thyroid carcinoma</p> <p>3. The patient has either metastatic disease or inoperable locally advanced disease</p> <p>4. The disease is progressive and is either symptomatic or imminently likely to become symptomatic</p> <p>5. The patient is treatment naïve to both vandetanib and cabozantinib unless the patient has had to discontinue cabozantinib within 3 months of starting cabozantinib because of toxicity (ie there is cabozantinib toxicity which cannot be managed by dose delay or dose modification) <u>and</u> there has been no disease progression whilst on cabozantinib</p> <p>Note: The sequential use of vandetanib and then cabozantinib is only funded if the patient has to discontinue vandetanib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on vandetanib. The use of cabozantinib after disease progression on or after vandetanib is not funded and vice versa</p> <p>6. The patient has an ECOG performance status of 0 or 1.</p> <p>7. Vandetanib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment</p> <p>8. A formal medical review as to whether treatment with vandetanib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment</p> <p>9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)</p> <p>10. Vandetanib is to be otherwise used as set out in its Summary of Product Characteristics</p>	From 29-Jul-16			Yes	Agreed	nca	nca	nca	nca

National Cancer Drugs Fund (CDF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients			Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Eligible for Interim Funding (Yes, No, Not currently applicable (NCA))	Interim Funding agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	CDF Managed Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
				Yes	Yes (but notice of removal served)	No						
VEN1_v1.0	Venetoclax	Treatment of chronic lymphatic leukaemia in the ABSENCE of 17p deletion (and absence of TP53 mutation if tested)	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Confirmed diagnosis of chronic lymphatic leukaemia or small lymphocytic lymphoma that requires treatment 3. Patient has been tested for 17p deletion and the result is negative. If TP53 mutation has been tested, then it must be negative too. 4. Patient must have progressive disease on or after chemoimmunotherapy 5. Patient must also either have progressive disease on or after treatment with a B cell receptor pathway inhibitor: a Bruton's tyrosine kinase inhibitor (BTKi eg ibrutinib) or a PI3K inhibitor (PI3Ki eg idelalisib) or have a contraindication to receiving both a BTKi and a PI3Ki. Please indicate which: ibrutinib, idelalisib or contraindication 6. Patient has an ECOG performance status of 0-2 7. Patients has been prospectively assessed for the risk of the development of tumour lysis syndrome following the start of venetoclax 8. Patient has been assessed specifically for potential drug interactions with venetoclax 9. Venetoclax is to be used as a single agent 10. Venetoclax is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment 11. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve) 12. Venetoclax to be otherwise used as set out in its Summary of Product Characteristics 	From 05-Oct-17			No	nca	nca	nca	Yes	nca
VEN2_v1.0	Venetoclax	The treatment of chronic lymphatic leukaemia in the PRESENCE of 17p deletion or TP53 mutation where all of the following criteria are met:	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Confirmed diagnosis of chronic lymphatic leukaemia or small lymphocytic lymphoma that requires treatment 3. Patient is positive for testing for 17p deletion or TP53 mutation 4. Patient must either have relapsed on or after a B cell receptor pathway inhibitor (a Bruton's tyrosine kinase inhibitor [BTKi eg ibrutinib] or a PI3K inhibitor [eg idelalisib]) or there must be a contraindication to the patient receiving both a BTKi and a PI3Ki. Please indicate which: ibrutinib, idelalisib or contraindication 5. Patient has a performance status of 0-2 6. Patients has been prospectively assessed for the risk of the development of tumour lysis syndrome following the start of venetoclax 7. Patient has been assessed specifically for potential drug interactions with venetoclax 8. Venetoclax is to be used as a single agent 9. Venetoclax is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment 10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve) 11. Venetoclax to be otherwise used as set out in its Summary of Product Characteristics 	From 05-Oct-17			No	nca	nca	nca	Yes	nca

National Cancer Drugs Fund (CDF) List

B. NICE approved and baseline funded drugs/indications from 1st April 2016

Notes: If no Blueteq approval criteria are set this is because this was not considered necessary at the time of approval. However Blueteq registration will be required for all cancer drugs moving from the CDF to baseline as a result of positive final NICE guidance from 7th December 2016.

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Abiraterone	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	<ol style="list-style-type: none"> 1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. I confirm that the patient has documented castration-resistant metastatic prostate cancer 3. I confirm that the patient has no or mild symptoms after androgen deprivation therapy has failed. 4. I confirm that chemotherapy is not yet indicated. 5. I confirm that ONE of the following applies to this patient: OPTION 1 - The patient has not previously received treatment with enzalutamide. OPTION 2 - The patient has previously received enzalutamide but it was stopped within 3 months of starting due to dose limiting toxicity and there is clear absence of disease progression. 6. I confirm abiraterone is to be given in combination with prednisolone. 7. I confirm the licensed dose and frequency of abiraterone will be used. 	Yes	TA387	27-Apr-16	26-Jul-16
Atezolizumab	Atezolizumab for treating previously platinum-treated locally advanced/ metastatic non squamos or squamos non-small cell lung cancer which has been prospectively determined before this application to be PD-L1 positive or PD-L1 negative or PD-L1 unquantifiable at PD-L1 assay or one in which PD-L1 status cannot be determined on account of insufficient lung cancer tissue being available for PD-L1 assay where all the following criteria are met:	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti -cancer therapy with atezolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis. 3. The patient has a histologically- or cytologically-confirmed diagnosis of stage IIIB or IV non-small cell lung cancer and is either non-squamous or squamous in type. 4. The patient has either progressed after previously receiving at least 2 cycles of platinum-containing chemotherapy for stage IIIB or IV non-small cell lung cancer and also a targeted treatment if the tumour is EGFR positive or ALK positive or progressed within 6 months of completing platinum-based chemotherapy given as adjuvant or neoadjuvant therapy or concurrent with radiotherapy 5. PD-L1 testing with an approved and validated test to determine the Tumour Proportion Score (TPS) has been attempted prior to this application. Either: - The TPS score will be documented - The TPS score cannot be documented as the TPS result was unquantifiable - PD-L1 testing was not possible as the pathologist has documented that there is insufficient tissue for PD-L1 analysis 6. The patient has a performance status (PS) of 0 or 1 and would otherwise be potentially fit for docetaxel-based 2nd line chemotherapy 7. The patient has no symptomatically active brain metastases or leptomeningeal metastases. 8. Atezolizumab will be administered as monotherapy 9. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody 10. Atezolizumab will be stopped at 2 years of treatment or on loss of clinical benefit or unacceptable toxicity, whichever occurs first. 11. A formal medical review as to whether treatment with atezolizumab should continue or not will be scheduled to occur at least by the end of the first 9 weeks of treatment 12. Treatment breaks of up to 12 weeks beyond the expected cycle length of atezolizumab are allowed solely to allow immune toxicities to settle 13. Atezolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) with the exception of criterion 10. 	No	TA520	16-May-18	14-Aug-18

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Atezolizumab	<p>Atezolizumab for locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy where all the following criteria are met:</p>	<ol style="list-style-type: none"> 1. The application is made by and the first cycle of systemic anti-cancer therapy with atezolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis 3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract 4. The patient's disease is either locally advanced (i.e. T4b any N or any T N2-3 disease) or metastatic (any T any N M1 disease) 5. The patient has either not received previous adjuvant chemotherapy, neoadjuvant chemotherapy or chemo-radiotherapy, or if previously treated with platinum-based chemotherapy whether as adjuvant chemotherapy or as neoadjuvant chemotherapy or with chemo-radiotherapy, has relapsed ≤ 12 months since completing the platinum-based chemotherapy* <p>* Patients meeting this criterion are eligible to be considered as previously treated for locally advanced/ metastatic disease (and can answer "Yes" to criteria 6 below) but must satisfy all other criteria</p> <ol style="list-style-type: none"> 6. There has been disease progression during or following previous platinum-based combination chemotherapy for inoperable locally advanced or metastatic urothelial cancer 7. The patient has an ECOG performance status (PS) score of 0 or 1 8. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PDL2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the atezolizumab compassionate use programme for this indication and the patient meets all other criteria listed here 9. Atezolizumab is being given as monotherapy and will commence at a fixed dose of 1200mg per infusion 10. A formal medical review as to whether treatment with atezolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment 11. The patient is to be treated until disease progression and loss of clinical benefit or excessive toxicity or patient choice, whichever is the sooner 12. The patient will receive a maximum treatment duration of 2 years 13. Treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle 14. The patient has no symptomatically active brain metastases or leptomeningeal metastases 15. Atezolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) 	No	TA525	13-Jun-18	13-Jul-18

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Avelumab	The treatment of previously treated (with systemic cytotoxic chemotherapy) metastatic Merkel cell carcinoma where all the following criteria are met:	1. An application is made by and the first cycle of systemic anti-cancer therapy with avelumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	No	TA517	11-Apr-18	10-Jul-18
		2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis				
		3. The patient has a confirmed histological or cytological diagnosis of Merkel cell carcinoma				
		4. The patient has metastatic disease				
		5. I confirm that the patient has previously been treated with cytotoxic chemotherapy for metastatic Merkel cell carcinoma and has not received any prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4] antibody				
		6. The patient has an ECOG performance status of either 0 or 1. Note: a patient with a performance status of 2 or more is not eligible for avelumab				
		7. If the patient has brain metastases, then these have been treated and are stable				
		8. Avelumab is to be used as monotherapy only				
		9. Avelumab is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment. I also confirm that patients with radiological disease progression not associated with significant clinical deterioration (defined as no new or worsening symptoms and no change in performance status for greater than 2 weeks and no need for salvage therapy: all 3 conditions must apply) can continue treatment				
		10. A formal medical review as to whether treatment with avelumab should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment				
		11. Treatment breaks of up to 12 weeks beyond the expected cycle length of avelumab are allowed but solely to allow immune toxicities to settle				
		12. Avelumab will otherwise be used as set out in its Summary of Product Characteristics (SPC)				
Bendamustine	The first line treatment of low grade lymphoma where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	n/a - NHS England clinical policy	-	08-Jul-18
		2. Low grade non-Hodgkin's lymphoma				
		3. Option for 1st-line chemotherapy only				
		4. To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication				
Note: Can be used in combination with Rituximab, which is commissioned by NHS England for this indication.						
Bendamustine	The first line treatment of mantle cell non-Hodgkin's lymphoma where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	n/a - NHS England clinical policy	-	08-Jul-18
		2. Mantle cell non-Hodgkin's lymphoma				
		3. 1st-line treatment in patients unsuitable for standard treatment				
		4. To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication				
Note: Can be used in combination with Rituximab, which is commissioned by NHS England for this indication.						

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Blinatumomab	The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in ADULT patients	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA450	27-Apr-17	26-Sep-17
		2. The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).				
		3. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy or inotuzumab ozagamicin				
		4. The patient is an adult* *note there is a separate Blueteq form to be used for blinatumomab in this indication in children.				
		5. Blinatumomab should only be requested by and administered in either bone marrow transplant centres or in major haematological centres that regularly treat patients with relapsed ALL and who have close and regular ALL multi-disciplinary team meetings and links with bone marrow transplant centres.				
		6. The patient has an ECOG performance status of 0 - 2.				
		7. A maximum of 5 cycles of treatment with blinatumomab will be administered.				
		8. Blinatumomab will be used as monotherapy				
		9. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		10. Blinatumomab should otherwise be used as set out in its Summary of Product Characteristics (SPC).				
Blinatumomab	The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in CHILD patients	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA450	27-Apr-17	26-Sep-17
		2. The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).				
		3. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy or inotuzumab ozagamicin				
		4. The patient is a child* and - is either post pubescent or - is pre pubescent and will receive blinatumomab at the dosage described in the phase 2 part of the blinatumomab trial protocol NCT01471782 and reported in J Clin Oncol 2016; 34: 4381-4389 *note there is a separate Blueteq form to be used for blinatumomab in this indication in adults.				
		5. Blinatumomab should only be requested by and administered in principal treatment centres				
		6. The use of the blinatumomab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.				
		7. The patient has a performance status of 0 - 2.				
		8. A maximum of 5 cycles of treatment with blinatumomab will be administered.				
		9. Blinatumomab will be used as monotherapy				
		10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		11. Trust policy regarding unlicensed treatments should be followed as blinatumomab is not licensed in this indication in children				
		12. Blinatumomab should otherwise be used as set out in its Summary of Product Characteristics (SPC).				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Bosutinib	Bosutinib for previously treated chronic myeloid leukaemia	1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	Yes	TA401	24-Aug-16	22-Nov-16
		2. I confirm the patient has chronic, accelerated or blast phase Philadelphia chromosome positive chronic myeloid leukaemia.				
		3. I confirm the patient has had previous treatment with 1 or more tyrosine kinase inhibitor.				
		4. I confirm that treatment is not appropriate with either imatinib, nilotinib or dasatinib.				
		5. I confirm the patient will receive the licensed dose and frequency of bosutinib				
Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant in ADULT patients where the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA446	28-Apr-17	26-Sep-17
		2. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.				
		3. The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant				
		4. The patient has never received brentuximab unless previously enrolled in the NCRI-adopted clinical trial called ECHELON-1				
		5. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response				
		6. The patient is an adult* *note there is a separate blueteq form to be used for brentuximab in this indication in children				
		7. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		8. No re-use of brentuximab will be used outside this indication unless previous partial/complete response to brentuximab and brentuximab is being used as a bridge to allogeneic stem cell transplant or donor lymphocyte infusion* *note there is a separate blueteq form for such re-use of brentuximab				
		9. A maximum of 16 cycles of brentuximab will be administered to the patient				
		10. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Bluteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant in CHLD patients where the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.</p> <p>3. The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant</p> <p>4. The patient has never received brentuximab</p> <p>5. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</p> <p>6. The patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002 http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378 *note there is a separate Bluteq form to be used for brentuximab in this indication in adults.</p> <p>7. The use of the brentuximab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.</p> <p>8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>9. No re-use of brentuximab will be used outside this indication unless previous partial/complete response to brentuximab and brentuximab is being used as a bridge to allogeneic stem cell transplant or donor lymphocyte infusion* *note there is a separate bluteq form for such re-use of brentuximab</p> <p>10. A maximum of 16 cycles of brentuximab will be administered to the patient</p> <p>11. Trust policy regarding unlicensed treatments has been followed as brentuximab is not licensed in this indication in children.</p> <p>12. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	Yes	TA446	28-Apr-17	26-Sep-17

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Brentuximab	Re-use of brentuximab in relapsed/refractory Hodgkin lymphoma in ADULT patients:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA446	28-Apr-17	26-Sep-17
		2. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.				
		3. The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant				
		4. Previous use of brentuximab achieved a partial/complete response to brentuximab				
		5. Brentuximab is being used as a bridge to allogeneic stem cell transplantation or donor lymphocyte infusion				
		6. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response				
		7. The patient is an adult* *note there is a separate blueteq form to be used for brentuximab in this indication in children				
		8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		9. A maximum of 16 cycles of brentuximab will be administered to the patient when combining this reuse and previous cycles of brentuximab				
		10. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				
Brentuximab	Re-use of brentuximab in relapsed/refractory Hodgkin lymphoma in CHILD patients:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA446	28-Apr-17	26-Sep-17
		2. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.				
		3. The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant				
		4. Previous use of brentuximab achieved a partial/complete response to brentuximab				
		5. Brentuximab is being used as a bridge to allogeneic stem cell transplantation or donor lymphocyte infusion				
		6. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response				
		7. The patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002 http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378 *note there is a separate Bluteq form to be used for brentuximab in this indication in adults.				
		8. The use of the brentuximab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.				
		9. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		10. A maximum of 16 cycles of brentuximab will be administered to the patient when combining this reuse and previous cycles of brentuximab				
		11. Trust policy regarding unlicensed treatments has been followed as brentuximab is not licensed in this indication in children.				
		12. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Brentuximab	The treatment of relapsed or refractory systemic anaplastic large cell lymphoma in ADULT patients, where the following criteria have been met:	<p>1. An application has been made and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has relapsed or refractory systemic anaplastic large cell lymphoma after front line chemotherapy Note: Brentuximab is not available for 1° cutaneous anaplastic large cell lymphoma unless it has transformed into systemic anaplastic large cell lymphoma</p> <p>3. Histologically confirmed CD30 positive disease</p> <p>4. The patient has never previously received brentuximab unless previously enrolled in the NCRI-adopted clinical trial called ECHELON-2</p> <p>5. Brentuximab is to be used as single-agent therapy</p> <p>6. The patient has an ECOG performance status of 0-1</p> <p>7. The patient is an adult Note: There is a separate blueteq form to be used for brentuximab in this indication in children</p> <p>8. Treatment with brentuximab to be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</p> <p>9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve) Note: Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>10. A maximum of 16 cycles of brentuximab may be administered per patient</p> <p>11. Brentuximab will be otherwise used as set out in its Summary of Product Characteristics</p>	Yes	TA478	04-Oct-17	02-Jan-18
Brentuximab	The treatment of relapsed or refractory systemic anaplastic large cell lymphoma in CHILD patients, where the following criteria have been met:	<p>1. An application has been made and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has relapsed or refractory systemic anaplastic large cell lymphoma after front line chemotherapy Note: Brentuximab is not available for 1° cutaneous anaplastic large cell lymphoma unless it has transformed into systemic anaplastic large cell lymphoma</p> <p>3. Histologically confirmed CD30 positive disease</p> <p>4. The patient has never previously received brentuximab unless previously enrolled in the NCRI-adopted clinical trial called ECHELON-2</p> <p>5. Brentuximab is to be used as single-agent therapy</p> <p>6. The patient has an ECOG performance status of 0-1</p> <p>7. The patient is a child* and either post pubescent or is pre pubescent and will receive brentuximab vedotin dosage as described in phase 2 of the trial protocol C25002 http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378 Note: there is a separate Blueteq form to be used for brentuximab vedotin in this indication in adults</p> <p>8. The use of brentuximab in this setting and in this patient has been discussed at a multi-disciplinary team (MDT) meeting which must include at least 2 consultants in the subspecialty with active and credible expertise in the relevant field of whom one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area</p> <p>9. Treatment with brentuximab to be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</p> <p>10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)* *Note: Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>11. Brentuximab vedotin will only be requested by and administered in principal treatment centres</p> <p>12. Trust policy regarding unlicensed treatments has been followed as brentuximab vedotin is not licensed in this indication in children</p> <p>13. A maximum of 16 cycles of brentuximab may be administered per patient</p> <p>14. Brentuximab will be otherwise used as set out in its Summary of Product Characteristics</p>	Yes	TA478	04-Oct-17	02-Jan-18

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Cabazitaxel	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel	1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	Yes	TA391	25-May-16	25-May-16
		2. I confirm the patient has hormone-relapsed metastatic prostate cancer.				
		3. I confirm the patient has received 225mg/m/sq or more of docetaxel and the disease has progressed during or after docetaxel chemotherapy.				
		4. I confirm cabazitaxel is to be prescribed in combination with prednisone or prednisolone.				
		5. I confirm the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.				
		6. I confirm the patient has been informed that treatment with cabazitaxel will be stopped if the disease progresses or after a maximum of 10 cycles (whichever happens first).				
		7. I confirm the licensed dose and frequency of cabazitaxel will be used.				
Cabozantinib	The treatment of previously treated advanced renal cell carcinoma where the following criteria are met:	1. An application has been made by and the first cycle of systemic anti -cancer therapy with cabozantinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA463	08-Nov-17	08-Nov-17
		2. The patient has a histological diagnosis of renal cell carcinoma with a clear cell component				
		3. The patient has either metastatic disease or inoperable locally advanced disease				
		4. The patient has previously received at least 1 vascular endothelial growth factor (VEGF)-targeted systemic therapy for renal cancer and has not been previously treated with cabozantinib				
		5. The patient has progressed on previous treatment or within 6 months of most recent dose of VEGF inhibitor				
		6. The patient has a performance status of 0 or 1				
		7. If the patient has brain metastases then these have been treated and are stable				
		8. Cabozantinib is to be continued until disease progression or unacceptable toxicity or the patient's choice to stop treatment				
		9. A formal medical review as to whether treatment with cabozantinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment				
		10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*				
		*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process.				
11. Cabozantinib will otherwise be used as set out in its Summary of Product Characteristics (SPC).						

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Cabozantinib	The treatment of medullary thyroid cancer where all the following criteria are met:	<p>1. This application is made by and the first cycle of systemic anti-cancer therapy with cabozantinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. This patient has a confirmed histological diagnosis of medullary thyroid carcinoma</p> <p>3. The patient has either metastatic disease or inoperable locally advanced disease</p> <p>4. The disease is progressive and is either symptomatic or imminently likely to become symptomatic</p> <p>5. The patient is treatment naïve to both cabozantinib and vandetanib unless the patient has had to discontinue vandetanib within 3 months of starting vandetanib because of toxicity (ie there is vandetanib toxicity which cannot be managed by dose delay or dose modification) <u>and</u> there has been no disease progression whilst on vandetanib</p> <p>Note: The sequential use of cabozantinib and then vandetanib is only funded if the patient has to discontinue cabozantinib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on cabozantinib. The use of vandetanib after disease progression on or after cabozantinib is not funded and vice versa</p> <p>6. The patient has an ECOG performance status of 0 or 1 or 2.</p> <p>7. Cabozantinib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment</p> <p>8. A formal medical review as to whether treatment with cabozantinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment</p> <p>9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)</p> <p>10. Cabozantinib is to be otherwise used as set out in its Summary of Product Characteristics</p>	Yes	TA516	28-Mar-18	26-Jun-18
Carfilzomib	The treatment of previously treated multiple myeloma where all the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has a diagnosis of multiple myeloma.</p> <p>3. The patient has relapsed or progressing disease.</p> <p>4. The patient has only received one line of prior treatment for myeloma (induction chemotherapy, followed by stem cell transplant is considered to be 1 line of therapy)</p> <p>5. The patient has received no prior treatment with Bortezomib.</p> <p>6. I confirm that the patient has a performance status (PS) 0 - 2.</p> <p>7. Carfilzomib will only be administered in combination with dexamethasone and no other systemic anticancer therapies (SACT).</p> <p>8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*</p> <p>9. Carfilzomib will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	Yes	TA475	19-Jul-17	17-Oct-17
Ceritinib	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer	<p>1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. I confirm the patient has a confirmed diagnosis (either histologically or cytologically) of stage IIIB or IV NSCLC that carries an ALK rearrangement.</p> <p>3. I confirm that the patient has been previously treated with crizotinib and the disease has progressed during or after therapy. Ceritinib is not funded for use following previous ALK inhibitor therapy other than with crizotinib.</p> <p>4. I confirm the licensed dose and frequency of ceritinib will be used.</p>	No	TA395	22-Jun-16	20-Sep-16

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Ceritinib	The first line treatment of anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	<ol style="list-style-type: none"> 1. The application is made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The patient has a histologically or cytologically confirmed diagnosis of stage IIIB or IV non small cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement 3. The patient has received no previous ALK-targeted therapy 4. The patient has received no previous cytotoxic chemotherapy for locally advanced or metastatic non small cell lung cancer ie no previous systemic treatment except when this has been given as neoadjuvant or adjuvant therapy or concurrently with radiotherapy 5. Ceritinib will be used only as single-agent therapy 6. The patient has an ECOG performance status of 0 or 1 or 2 7. The patient either has no brain metastases or, if the patient has brain metastases, the patient is symptomatically stable prior to starting ceritinib 8. The patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner 9. Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle 10. Ceritinib will be otherwise used as set out in its Summary of Product Characteristics 11. In cases of intolerance to ceritinib, either alectinib or crizotinib is to be used only if the patient has not had progressive disease whilst on ceritinib. Neither alectinib or crizotinib are to be used following disease progression on ceritinib as there is no current clear evidence to support treatment with alectinib or crizotinib after disease progression on ceritinib 	No	TA500	24-Jan-18	24-Apr-18
Cetuximab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Metastatic colorectal cancer with no previous treatment for metastatic disease 3. RAS wild-type metastatic colorectal cancer 4. Cetuximab will be given in combination with Irinotecan-based combination chemotherapy 5. Cetuximab will be given as a 2-weekly regimen at a dose of 500mg/m² 6. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below) <p>Note: No treatment breaks of more than 4 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)</p> <p>Note: If excessive toxicity with irinotecan, cetuximab can be continued with a fluoropyrimidine alone until disease progression only.</p> <p>Note: * Patients with potentially resectable metastatic disease who receive cetuximab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with cetuximab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug. * Additionally patients who have successful resection(s) after neoadjuvant cetuximab may receive cetuximab with subsequent first-line treatment if they present later with advanced disease. * Cetuximab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.</p>	Yes	TA439	29-Mar-17	27-Jun-17

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Cetuximab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA439	29-Mar-17	27-Jun-17
		2. Metastatic colorectal cancer with no previous treatment for metastatic disease				
		3. RAS wild-type metastatic colorectal cancer				
		4. Cetuximab will be given in combination with oxaliplatin-based combination chemotherapy				
		5. Cetuximab will be given as a 2-weekly regimen at a dose of 500mg/m ²				
		6. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below).				
		Note: No treatment breaks of more than 4 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)				
Cetuximab	The first line treatment of recurrent/metastatic oral cavity cancer where the following criteria are met:	Note:	Yes	TA473	31-Aug-17	31-Aug-17
		* Patients with potentially resectable metastatic disease who receive cetuximab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with cetuximab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug.				
		* Additionally patients who have successful resection(s) after neoadjuvant cetuximab may receive cetuximab with subsequent first-line treatment if they present later with advanced disease.				
		* Cetuximab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.				
		1. An application has been made and the first cycle of systemic anti -cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
		2. The patient has a confirmed histological diagnosis of squamous cell carcinoma.				
		3. The patient has a primary tumour that originated in the oral cavity.				
		4. The patient has recurrent and/or metastatic disease.				
		5. The patient has not received any previous systemic chemotherapy for this oral cavity tumour unless it was part of multimodality treatment for locally advanced disease and was completed more than 6 months previously.				
		6. Treatment will be given with palliative intent.				
		7. Cetuximab is to only be used in combination with a maximum of 6 cycles of platinum-based combination chemotherapy followed by single agent cetuximab as maintenance therapy.				
		8. The patient has received no previous treatment with cetuximab for head and neck cancer.				
		9. The patient has a performance status of 0-1.				
10. Cetuximab is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment, whichever is the sooner.						
11. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).						
12. Consideration has been to be given to administration of cetuximab 500mg/m ² every 2 weeks (e.g. if chemotherapy is scheduled on a 4 week cycle or during the maintenance phase of single agent cetuximab therapy).						
13. Cetuximab will be otherwise used as set out in its Summary of Product Characteristics.						
Crizotinib	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA406	28-Sep-16	28-Dec-16
		2. I confirm the patient has a histologically or cytologically conformed diagnosis of stage IIIB or IV nonsmall-cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement				
		3. I confirm the patient has had no previous 1st line systemic therapy (chemotherapy or other ALK inhibitors) for advanced or metastatic non-small cell lung cancer unless any NICE-approved 1st line ALK inhibitor therapy has had to be discontinued on account of unacceptable toxicity AND there is no evidence of disease progression				
		4. I confirm the patient will receive the licensed dose and frequency of crizotinib.				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Crizotinib	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA422	21-Dec-16	21-Mar-17
		2. I confirm the patient has a histologically or cytologically conformed diagnosis of stage IIIB or IV nonsmall-cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement				
		3. I confirm this is a 2nd or subsequent line treatment post 1st line platinum based combination chemotherapy and that the patient has not previously been treated with another ALK inhibitor				
		4. I confirm the patient will receive crizotinib as set out in its Summary of Product Characteristics				
Dabrafenib and Trametinib	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA396	22-Jun-16	20-Sep-16
		2. I confirm the patient has a confirmed diagnosis, histologically, of stage III (unresectable) or stage IV melanoma with a BRAF V600 mutation only.				
		3. I confirm the licensed dose and frequency of dabrafenib and trametinib will be used*. *The only exception to this is for patients enrolled in the NIHR-approved INTERIM trial where intermittent treatment is allowed can be given in the experimental arm				
Dasatinib	Dasatinib for the treatment of untreated chronic phase chronic myeloid leukaemia	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA426	21-Dec-16	21-Mar-17
		2. I confirm that the patient has chronic phase myeloid leukaemia				
		3. I confirm that the patient has received no prior treatment unless it was dasatinib received as part of the SPIRIT 2 trial for this indication and the patient meets all other criteria listed here* *In March 2018 patients previously entered into the Spirit 2 trial and receiving free-of-charge supplies of dasatinib can transition to NHS commercial supply.				
		4. I confirm that imatinib is not appropriate for this patient and that this has been discussed and supported by the relevant MDT involved in CML decision making unless they are already receiving dasatinib as part of the SPIRIT 2 trial for this indication and the patient meets all other criteria listed here				
		5. I confirm that dasatinib will be used as outlined in the Summary of Product Characteristics (SPC).				
Enzalutamide	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy	nca	Yes	TA377	27-Jan-16	26-Apr-16
Eribulin	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a	Yes	TA423	21-Dec-16	21-Dec-16
		2. I confirm that the patient has advanced breast cancer				
		3. I confirm that the patient has had at least 2 prior chemotherapy regimens for advanced disease				
		4. I confirm the licensed dose and frequency of eribulin will be used.				
Everolimus	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	Yes	TA421	21-Dec-16	21-Dec-16
		2. I confirm that the patient has ER +ve, HER2 -ve metastatic breast cancer				
		3. I confirm that the patient has no symptomatic visceral disease				
		4. I confirm that everolimus will be given in combination with exemestane				
		5. I confirm that the patient has had previous treatment with a non-steroidal aromatase inhibitor				
		6. I confirm that the patient has had no previous treatment with exemestane for metastatic breast cancer				
		7. I confirm that the patient has had no more than one line of chemotherapy for the treatment of advanced breast cancer				
7. I confirm the licensed dose and frequency of everolimus will be used.						
Everolimus	Everolimus for advanced renal cell carcinoma after previous treatment	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA432	22-Feb-17	23-May-17
		2. I confirm that the patient has biopsy proven renal cell carcinoma				
		3. I confirm that the patient has progressed during or after treatment with vascular endothelial growth factor targeted therapy				
		4. I confirm that the use of everolimus will be as per the Summary of Product Characteristics (SPC)				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Everolimus	The treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA449	13-May-17	26-Sep-17
		2. The patient has histopathologically proven well differentiated neuroendocrine tumour of pancreatic origin				
		3. The patient has unresectable or metastatic disease				
		4. The patient has exhibited disease progression in past 12 months				
		5. The patient has a performance status of 0-1				
		6. The patient has had no previous treatment with a mTOR inhibitor.				
		7. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		8. Everolimus will otherwise be used as set out in its Summary of Product Characteristics (SPC).				
Everolimus	The treatment of unresectable or metastatic neuroendocrine tumours of gastrointestinal or lung origin with disease progression where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA449	13-May-17	26-Sep-17
		2. The patient has histopathologically proven well differentiated neuroendocrine tumour of gastrointestinal or lung origin				
		3. The patient has unresectable or metastatic disease				
		4. The patient has no history of and no active symptoms to suggest a functional tumour				
		5. The patient has exhibited disease progression in past 12 months				
		6. The patient has a performance status of 0-1				
		7. The patient has had no previous treatment with a mTOR inhibitor.				
		8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		9. Everolimus will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Ibrutinib	<p>Ibrutinib for previously treated chronic lymphocytic leukaemia in patients failing to respond to chemoimmunotherapy OR having a progression-free interval of <3 years with the preceding treatment OR having a progression free interval of ≥3 years with the preceding treatment and comorbidities which contraindicate consideration of further chemoimmunotherapy where the following criteria are met:</p> <p>NOTE: there is a separate form for the funding of ibrutinib in patients with a progression-free interval of ≥3 years with the preceding treatment and who do not have comorbidities which contraindicate consideration of chemoimmunotherapy</p>	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti -cancer therapy with ibrutinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. The patient has relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) and in whom there is now an indication for treatment with systemic therapy 3. The patient has received at least one prior anti-CD20 - containing chemoimmunotherapy for CLL/SLL 4. The patient is considered not appropriate for treatment or retreatment with chemoimmunotherapy for one of the reasons outlined below. Please indicate below whether this is due to one of the following; - Failure to respond to preceding chemoimmunotherapy OR - A progression-free interval of less than 3 years with the preceding line of therapy OR - A progression-free interval of ≥3 years with the preceding line of therapy AND the presence of comorbidities which contraindicate consideration of chemoimmunotherapy NOTE: there is a separate form for the funding of ibrutinib in patients with a progression-free interval of ≥3 years with the preceding treatment and who do not have comorbidities which contraindicate consideration of chemoimmunotherapy 5. The patient has a performance status of ECOG 0-2 6. The patient has a neutrophil count of ≥ 0.75 x 10⁹/l unless due to underlying disease 7. The patient has a platelet count of ≥ 30 x 10⁹/l unless due to underlying disease 8. The patient is not on warfarin or strong CYP3A4/5 inhibitors 9. The patient has had no prior treatment with idelalisib unless idelalisib has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression 10. No treatment breaks of more than 6 weeks beyond the expected 4-weekly cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process. 11. Ibrutinib will otherwise be used as set out in its Summary of Product Characteristics (SPC) 	Yes	TA429	25-Jan-17	25-Apr-17
Ibrutinib	<p>Ibrutinib for previously treated chronic lymphocytic leukaemia in patients with a progression-free interval of ≥3 years with the preceding treatment and who do not have comorbidities which contraindicate consideration of chemoimmunotherapy where the following criteria are met:</p> <p>NOTE: there is a separate form for the funding of ibrutinib in patients failing to respond to chemoimmunotherapy OR having a progression-free interval of <3 years with the preceding treatment OR having a progression free interval of ≥3 years with the preceding treatment and who have comorbidities which contra-indicate consideration of further chemoimmunotherapy</p>	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti -cancer therapy with ibrutinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. The patient has relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) and in whom there is now an indication for treatment with systemic therapy 3. The patient has received at least one prior anti-CD20 - containing chemoimmunotherapy for CLL/SLL 4. The patient has a progression-free interval of ≥3 years with the preceding line of therapy AND there has been a fully informed discussion with the patient as to the advantages and disadvantages of the treatment options of ibrutinib and chemoimmunotherapy and that the outcome of this discussion is for treatment with ibrutinib NOTE: there is a separate form for the funding of ibrutinib in patients failing to respond to chemoimmunotherapy OR having a progression-free interval of <3 years with the preceding treatment OR having a progression free interval of ≥3 years with the preceding treatment and who have comorbidities which contra-indicate consideration of further chemoimmunotherapy 5. The patient has a performance status of ECOG 0-2 6. The patient has a neutrophil count of ≥ 0.75 x 10⁹/l unless due to underlying disease 7. The patient has a platelet count of ≥ 30 x 10⁹/l unless due to underlying disease 8. The patient is not on warfarin or strong CYP3A4/5 inhibitors 9. The patient has had no prior treatment with idelalisib unless idelalisib has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression 10. No treatment breaks of more than 6 weeks beyond the expected 4-weekly cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process. 11. Ibrutinib will otherwise be used as set out in its Summary of Product Characteristics (SPC) 	Yes	TA429	25-Jan-17	25-Apr-17

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Ibrutinib	Ibrutinib for the treatment of chronic lymphocytic leukaemia with 17p deletion or TP53 mutation	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA429	25-Jan-17	25-Apr-17
		2. The patient has Chronic lymphocytic leukaemia (CLL) or Small lymphocytic leukaemia (SLL) with a 17p deletion or TP53 mutation				
		3. The patient is not appropriate for chemo-immunotherapy				
		4. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2				
		5. The patient has a neutrophil count of $\geq 0.75 \times 10^9/l$ unless due to underlying disease				
		6. The patients has a platelet count of $\geq 30 \times 10^9/l$ unless due to underlying disease				
		7. The patient is not taking either warfarin or strong CYP3A4/5 inhibitors				
		8. The patient has had no prior treatment with idelalisib unless idelalisib has had to be stopped within 6 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression.				
		9. Ibrutinib will be used as outlined in the Summary of Product Characteristics (SPC).				
Ibrutinib	The treatment of relapsed or refractory mantle cell lymphoma in patients who have received only 1 prior line of systemic therapy where all the following criteria are met:	1. The application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	Yes	TA502	31-Jan-18	01-May-18
		2. The patient has a confirmed histopathological diagnosis of mantle cell lymphoma				
		3. The patient has been previously been treated with one prior line of rituximab-containing chemotherapy ONLY . Induction chemotherapy followed by maintenance rituximab or induction chemotherapy followed by stem cell transplantation count as 1 line				
		4. Presence of relapsed/refractory mantle cell lymphoma with documented progression of disease during or following rituximab-containing 1st line chemotherapy				
		5. The patient has never received any B cell receptor therapies (ibrutinib or other Bruton's tyrosine kinase inhibitors)				
		6. Ibrutinib is to be used as a single agent				
		7. Ibrutinib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment				
		8. The patient's performance status is 0 or 1 or 2				
		9. The patient is not on concurrent therapy with warfarin or CYP3A4/5 inhibitors				
		10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		11. Ibrutinib will be otherwise used as set out in its Summary of Product Characteristics				
Ipilimumab and Nivolumab	Nivolumab in combination with ipilimumab for treating advanced melanoma	1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA400	27-Jul-16	25-Oct-16
		2. I confirm the patient has stage III (unresectable) or stage IV histologically confirmed melanoma.				
		3. I confirm that the patient is of performance status (PS) 0 or 1.				
		4. I confirm that the patient has not received previous treatment with any of anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody for metastatic disease.				
		5. I confirm that the patient has only received allowed prior systemic therapy* *Allowed prior therapy is 1) prior adjuvant therapy with immune checkpoint inhibitors when given as part of a clinical trial either as monotherapy or in combination with ipilimumab and/or 2) BRAF/MEK inhibitor targeted therapies when given for advanced disease; prior adjuvant therapy with ipilimumab + nivolumab is not allowed				
		6. I confirm the patient has no symptomatic brain metastases or leptomeningeal metastases currently requiring steroids for symptom control.				
		7. I confirm the licensed doses and frequencies of nivolumab and ipilimumab will be used.				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Lenvatinib with everolimus	The treatment of previously treated advanced renal cell carcinoma	1. The application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	No	TA498	24-Jan-18	24-Apr-18
		2. The patient has a confirmed histological diagnosis of renal cell carcinoma with a clear cell component				
		3. The patient has either metastatic disease or inoperable locally advanced disease				
		4. The patient has previously received only 1 vascular endothelial growth factor (VEGF)-targeted systemic therapy for advanced/metastatic renal cancer*				
		5. The patient has progressed on previous treatment or within 6 months of discontinuing previous treatment				
		6. The patient has an ECOG performance status of either 0 or 1* *Patients with a performance status of 2 or more are not eligible for lenvatinib with everolimus				
		7. The patient has received no previous treatment with either lenvatinib or everolimus				
		8. The patient either has no brain metastases or, if the patient has brain metastases, then these have been treated and are symptomatically stable				
		9. Lenvatinib with everolimus will be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment				
		10. If unacceptable toxicity occurs, the daily doses of lenvatinib and, if necessary, everolimus are to be modified as needed according to the dose/management plan as set out in section 4.2 of the Summary of Product Characteristics for lenvatinib (Kisplyx)				
		11. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		12. Lenvatinib (Kisplyx) and everolimus are to be otherwise used as set out in their Summaries of Product Characteristics				
Nab-paclitaxel with gemcitabine	The treatment of untreated metastatic pancreatic cancer only if other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	No	TA476	06-Sep-17	05-Dec-17
		2. Confirmed histological or cytological diagnosis of pancreatic adenocarcinoma				
		3. Patient must have metastatic disease (patients with locally advanced disease are ineligible)				
		4. Patient has not received any previous systemic chemotherapy for the pancreatic cancer unless given as a radiosensitiser in the adjuvant setting and completed at least 6 months previously				
		5. Nab-paclitaxel is to be used only in combination with gemcitabine				
		6. Nab-paclitaxel plus gemcitabine is to be used as 1 st line treatment only				
		7. Patient has a performance status of 0 or 1				
		8. Patient is not considered to be a suitable candidate for oxaliplatin- and irinotecan-based combination chemotherapy and would otherwise receive gemcitabine monotherapy				
		9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		10. Nab-paclitaxel to be otherwise used as set out in its Summary of Product Characteristics				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Nilotinib	Nilotinib for the treatment of untreated chronic phase chronic myeloid leukaemia	1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA426	21-Dec-16	21-Mar-17
		2. I confirm that the patient has chronic phase myeloid leukaemia				
		3. I confirm that the patient has received no prior treatment				
		4. I confirm that imatinib is not appropriate for this patient and that this has been discussed and supported by the relevant MDT involved in CML decision making				
		5. I confirm that nilotinib will be used as outlined in the Summary of Product Characteristics (SPC).				
Nivolumab	The treatment of relapsed or refractory classical Hodgkin Lymphoma in ADULT patients where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA462	26-Aug-17	26-Aug-17
		2. The prescribing clinician is aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis				
		3. The patient has a histologically confirmed diagnosis of classical Hodgkin's Lymphoma				
		4. The patient has relapsed or refractory disease				
		5. The patient has received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as part of previous therapy for classical Hodgkin's Lymphoma				
		6. The patient has had prior treatment with brentuximab vedotin				
		7. The patient has an ECOG performance status (PS) 0-1				
		8. The patient is an adult*. *note there is a separate Blueteq form to be used for nivolumab in this indication in children.				
		9. Nivolumab will be given as monotherapy.				
		10. The patient has no known central nervous system lymphoma.				
		11. The patient has not received prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless received as part of the nivolumab EAMS programme for this indication and meeting all other criteria listed.				
		12. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Bluteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Nivolumab	The treatment of relapsed or refractory classical Hodgkin Lymphoma in PAEDIATRIC patients where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	-	26-Aug-17	26-Aug-17
		2. The prescribing clinician is aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.				
		3. The patient has a histologically confirmed diagnosis of classical Hodgkin's Lymphoma				
		4. The patient has relapsed or refractory disease				
		5. The patient has received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as part of previous therapy for classical Hodgkin's Lymphoma				
		6. The patient has had prior treatment with brentuximab vedotin				
		7. The patient has an ECOG performance status (PS) 0-1				
		8. The patient is a child* and either post pubescent or is pre pubescent and will receive nivolumab dosage as described in the publication Blood 2016; 128: 5414 *note there is a separate Bluteq form to be used for nivolumab in this indication in adults.				
		9. Nivolumab will be given as monotherapy.				
		10. The patient has no known central nervous system lymphoma.				
		11. Nivolumab will only be requested by and administered in principal treatment centres.				
		12. The use of the nivolumab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.				
		13. I confirm that Trust policy regarding unlicensed treatments has been followed as nivolumab is not licensed in this indication in children.				
		14. The patient has not received prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.				
		15. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Nivolumab	Nivolumab for previously treated advanced renal cell carcinoma	1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA417	23-Nov-16	23-Dec-16
		2. I confirm the patient has advanced or metastatic histologically proven renal cell carcinoma with clear cell component.				
		3. I confirm the patient has been previously treated with only 1 or 2 previous lines of antiangiogenic therapy				
		4. I confirm the patient's Karnofsky performance status (KPS) is 70 or more.				
		5. I confirm the patient will receive the licensed dose and frequency of nivolumab				
Obinutuzumab	The treatment of untreated advanced follicular lymphoma where all the following criteria are met:	1. This application is made by and the first cycle of obinutuzumab in combination with chemotherapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	No	TA513	21-Mar-18	19-Jun-18
		2. The patient has a confirmed histological diagnosis of grade 1-3a CD20-positive follicular lymphoma				
		3. The patient has not previously received any of the following for treatment of lymphoma: chemotherapy alone, immunotherapy alone (rituximab, obinutuzumab) or chemotherapy in combination with immunotherapy (rituximab, obinutuzumab).				
		4. The patient has been assessed according to the Follicular Lymphoma International Prognostic Index (FLIPI) and has scored a value of at least 2. Please indicate FLIPI score: Follicular Lymphoma International prognostic Index (FLIPI) scoring system 1. Age: if < 60 years, score 0; if ≥ 60 years, score 1 2. Serum LDH: if in normal range, score 0; if raised above normal range, score 1 3. Haemoglobin level: if ≥ 120g/L, score 0; if < 120g/L, score 1 4. Ann Arbor stage: if stage I or II, score 0; if stage III or IV, score 1 5. Number of involved nodal areas: if ≤ 4, score 0; if ≥ 5, score 1. Each of the following is considered a single nodal area: left cervical, right cervical, left axillary, right axillary, mediastinal (includes hilar, paratracheal and retrocrural areas), mesenteric (includes coeliac, splenic and portal areas), para-aortic (includes common iliac and external iliac areas), left inguinal (includes left femoral area), right inguinal (includes right femoral area), other (eg epitrochlear, popliteal areas)				
		5. The patient has bulky stage II disease (>7cm) or stage III disease or stage IV disease. Patients with stage I disease or non-bulky stage II disease are not eligible for obinutuzumab				
		6. Obinutuzumab is to be given in combination with induction combination chemotherapy for either: a maximum of 6 cycles if given with bendamustine or a maximum 6 cycles if given with CHOP or a maximum 8 cycles if given with CVP				
		7. On completion of induction chemotherapy in combination with obinutuzumab, only patients having at least a documented partial response to treatment will commence maintenance therapy with single agent obinutuzumab once every 2 months for a maximum of 2 years or until disease progression (whichever occurs first)				
		8. The patient has an ECOG performance status of 0, 1 or 2				
		9. A formal medical review as to whether treatment with obinutuzumab in combination with chemotherapy should continue or not will be scheduled to occur at least by the end of the third cycle of treatment				
		10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		11. Obinutuzumab is to be otherwise used as set out in its Summary of Product Characteristics				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Olaparib	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy	nca	No	TA381	27-Jan-16	26-Apr-16
Palbociclib (in combination with an aromatase inhibitor)	The treatment of hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Histologically or cytologically documented oestrogen receptor positive and her-2 negative breast cancer 3. I confirm that the patient has had no prior treatment with a CDK 4/6 inhibitor unless either ribociclib has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression or palbociclib has been received as part of the compassionate use scheme and the patient meets all the other criteria 4. Metastatic breast cancer or locally advanced breast cancer not amenable to curative treatment 5. The patient is male or is female and either post-menopausal or if pre- or peri-menopausal has undergone ovarian ablation or suppression with LHRH agonist treatment 6. No previous hormone therapy for locally advanced or metastatic disease i.e. is hormone therapy naïve for locally advanced/metastatic breast cancer. Previous hormone therapy with anastrozole or letrozole whether as adjuvant therapy or as neoadjuvant treatment is allowed as long as the patient has had a disease-free interval of 12 months or more since completing treatment with anastrozole or letrozole. 7. Palbociclib will only be given in combination with an aromatase inhibitor 8. Patients have an ECOG performance status of 0-2 9. Patients will be treated until progressive disease or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner 10. Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle 11. Palbociclib will be otherwise used as set out in its Summary of Product Characteristics (SPC) 	Yes	TA495	20-Dec-17	20-Mar-18

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Panitumumab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA439	29-Mar-17	27-Jun-17
		2. Metastatic colorectal cancer with no previous treatment for metastatic disease				
		3. RAS wild-type metastatic colorectal cancer				
		4. Panitumumab will be given in combination with Irinotecan-based combination chemotherapy				
		5. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below)				
		Note: No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)				
		Note: If excessive toxicity with irinotecan, panitumumab can be continued with a fluoropyrimidine alone until disease progression only.				
Note: * Patients with potentially resectable metastatic disease who receive panitumumab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with panitumumab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug. * Additionally patients who have successful resection(s) after neoadjuvant panitumumab may receive panitumumab with subsequent first-line treatment if they present later with advanced disease. * Panitumumab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.						
Panitumumab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA439	29-Mar-17	27-Jun-17
		2. Metastatic colorectal cancer with no previous treatment for metastatic disease				
		3. RAS wild-type metastatic colorectal cancer				
		4. Panitumumab will be given in combination with oxaliplatin-based combination chemotherapy				
		5. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below)				
		Note: No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)				
		Note: If excessive toxicity with oxaliplatin, panitumumab can be continued with a fluoropyrimidine alone until disease progression only.				
Note: * Patients with potentially resectable metastatic disease who receive panitumumab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with panitumumab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug. * Additionally patients who have successful resection(s) after neoadjuvant panitumumab may receive panitumumab with subsequent first-line treatment if they present later with advanced disease. * Panitumumab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.						

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Panobinostat	Panobinostat for treating multiple myeloma after at least 2 previous treatments	nca	No	TA380	27-Jan-16	26-Apr-16
Pembrolizumab	The treatment of PD-L1-positive non small cell lung cancer after chemotherapy	<p>1. An application has been made by and the first cycle of systemic anti -cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</p> <p>2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</p> <p>3. The patient has a histologically- or cytologically-confirmed diagnosis of stage IIIB or IV non-small cell lung cancer (squamous or non-squamous).</p> <p>4. The patient's tumour expresses PD-L1 (that is, with a tumour proportion score [TPS] $\geq 1\%$) by an approved and validated test.</p> <p>5. The patient has progressed after treatment with at least two cycles of platinum-containing doublet chemotherapy for stage IIIB/IV disease AND a targeted treatment if they have an EGFR or ALK-positive tumour.</p> <p>6. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.</p> <p>7. The patient has no active brain metastases or leptomeningeal metastases.</p> <p>8. The patient has not received prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4) antibody.</p> <p>9. Pembrolizumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first.</p>	No	TA428	11-Jan-17	11-Feb-17

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Pemetrexed	Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309)	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	Yes	TA402	24-Aug-16	24-Aug-16
		2. I confirm the patient has locally advanced or metastatic non-squamous non-small cell lung cancer				
		3. I confirm pemetrexed is to be given as maintenance therapy following 1st line induction chemotherapy with cisplatin and pemetrexed* which has not progressed immediately after 4 cycles of such chemotherapy. * The evidence for the use of maintenance pemetrexed following induction chemotherapy with the combination of pemetrexed and carboplatin has not been established and is therefore not approved				
		4. I confirm the patient's Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1 at the start of maintenance treatment.				
Pertuzumab	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. NOTE: The application should be made immediately prior to commencing pertuzumab when given with single agent docetaxel chemotherapy plus trastuzumab as part of sequential anthracycline/docetaxel regimen and not at the start of the anthracycline based component.	No	TA424	21-Dec-16	21-Mar-17
		2. I confirm that pertuzumab treatment is being given with neoadjuvant intent.				
		3. I confirm that the patient has T2-T4b and/or histologically/cytologically proven node positive disease and that the patient also had M0 disease.				
		4. I confirm the patient has HER2 3+ by IHC or FISH/CISH positive disease.				
		5. I confirm the baseline LVEF is greater than or equal to 55%.				
		6. I confirm there has been no prior treatment with chemotherapy or HER2 therapy for this breast cancer.				
		7. I confirm that ONE of the following applies to this patient: the patient will have a maximum of 4 cycles of pertuzumab if given with single agent docetaxel chemotherapy plus trastuzumab as part of sequential anthracycline/docetaxel regimen; OR the patient will have a maximum of 6 cycles of pertuzumab only if given with combination of docetaxel and carboplatin chemotherapy plus trastuzumab; OR the patient will have maximum of 4 cycles of pertuzumab only if given with the first 4 cycles of chemotherapy in either arm of the NIHR-approved ROSCO neoadjuvant trial.				
		8. I confirm that ONE of the following applies to this patient: pertuzumab is to be given in combination with docetaxel-containing chemotherapy plus intravenous trastuzumab*; OR the patient is enrolled in the NIHR-approved neoadjuvant trial where pertuzumab can be given with chemotherapy in either arm of the study. *Trastuzumab should be given IV when given in combination with pertuzumab but trastuzumab may be given IV or sc when given as a single agent in the adjuvant phase.				
		9. I confirm the patient will receive the licensed dose and frequency of pertuzumab*. *Pertuzumab is only to be given in combination with intravenous trastuzumab. The use of pertuzumab will not be funded if given with subcutaneous trastuzumab. *If the patient has a severe allergic reaction to docetaxel and is re-challenged with docetaxel unsuccessfully, neoadjuvant chemotherapy with pertuzumab and intravenous trastuzumab can be completed with paclitaxel replacing the docetaxel				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Pertuzumab	The first line treatment of locally advanced or metastatic breast cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA509	07-Mar-18	05-Jun-18
		2. Locally advanced or metastatic breast cancer				
		3. HER2 3+ or FISH positive breast cancer				
		4. ECOG PS 0 or 1				
		5. Any adjuvant HER2 therapy should have been completed more than 12 months prior to metastatic diagnosis				
		6. No prior treatment with chemotherapy or HER2 therapy for metastatic disease				
		7. The patient will receive pertuzumab as first line treatment in combination with docetaxel and IV trastuzumab* *The use of pertuzumab is only funded when given with intravenous trastuzumab. Use of pertuzumab with subcutaneous trastuzumab will not be funded				
		8. I confirm that pertuzumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).* *If a patient commences 1st line treatment with docetaxel and has a severe allergic reaction to the docetaxel and is re-challenged with docetaxel unsuccessfully, chemotherapy with the combination of paclitaxel, pertuzumab and intravenous trastuzumab can be used but only in these specific circumstances. *Not to be used beyond first disease progression outside the CNS. Do not discontinue if disease progression is within the CNS alone.				
Pomalidomide	Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No	TA427	11-Jan-17	11-Apr-17
		2. I confirm the the patient has multiple myeloma				
		3. I confirm the patients performance status (PS) is 0-2				
		4. I confirm the patient has previously received 3 lines of treatment with adequate trials of at least all of the following options of therapy: bortezomib, lenalidomide and alkylating agents				
		5. I confirm that the patient has refractory disease to previous line of treatment				
		6. I confirm that pomalidomide will be used as outlined in the Summary of Product Characteristics (SPC).				
Ponatinib	The treatment of chronic phase, accelerated phase or blast phase chronic myeloid leukaemia where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA451	13-Feb-17	26-Sep-17
		2. The patient has chronic phase, accelerated phase or blast phase chronic myeloid leukaemia				
		3. The disease is resistant to dasatinib or nilotinib, or the patient cannot have dasatinib nor nilotinib and imatinib is not clinically appropriate, or the T315I gene mutation is present				
Ponatinib	The treatment of Philadelphia chromosome positive acute lymphoblastic leukaemia where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA451	13-Feb-17	26-Sep-17
		2. The patient has Philadelphia chromosome positive acute lymphoblastic leukaemia				
		3. Imatinib is not clinically appropriate for the patient or the T315I gene mutation is present				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Radium-223	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	Yes	TA412	28-Sep-16	28-Dec-16
		2. I confirm that the patient has histologically or cytologically confirmed adenocarcinoma of the prostate who has hormone-refractory disease with two or more bone metastases detected on skeletal scintigraphy OR the patient has a high clinical suspicion of prostate cancer with a high PSA value (>100ng/ml) and who has hormone-refractory disease with two or more bone metastases detected on skeletal scintigraphy.				
		3. I confirm the patient has symptomatic bone metastases with regular use of analgesic medication or treatment with external-beam radiation therapy required for cancer related bone pain within the previous 12 weeks.				
		4. I confirm the patient has no known visceral metastases and no previous history of visceral spread.				
		5. I confirm the patient has no malignant lymphadenopathy that is more than 3cm in diameter.				
		6. I confirm the patient's Performance Status is 0-2				
		7. I confirm the patient has no imminent or established spinal cord compression.				
		8. I confirm the patient has had no previous hemibody external radiotherapy or systemic radiotherapy with radioisotopes within the previous 24 weeks				
		9. I confirm that the patient has already had prior docetaxel OR docetaxel is contraindicated or the patient is not suitable for docetaxel				
		10. I confirm that a sufficient trial of treatment with abiraterone or enzalutamide has been given to relieve bone symptoms before consideration of radium-223.				
		11. I confirm that the use of radium-223 will be as per the Summary of Product Characteristics (SPC).				
Regorafenib	The treatment of previously treated unresectable or metastatic gastrointestinal stromal tumours where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	Yes	TA488	15-Nov-17	14-Feb-18
		2. Patient has histologically confirmed, metastatic or unresectable GIST				
		3. Patient has ECOG performance status (PS) 0-1				
		4. Patient has had disease progression on or intolerance to previous imatinib				
		5. Patient has had disease progression on or intolerance to previous sunitinib				
		6. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		7. Regorafenib to be otherwise used as set out in its Summary of Product Characteristics				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Ribociclib (in combination with an aromatase inhibitor)	The treatment of hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Histologically or cytologically documented oestrogen receptor positive and her-2 negative breast cancer 3. I confirm that the patient has had no prior treatment with a CDK 4/6 inhibitor unless either palbociclib has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression or ribociclib has been 4. Metastatic breast cancer or locally advanced breast cancer not amenable to curative treatment 5. The patient is male or is female and either post-menopausal or if pre- or peri-menopausal has undergone ovarian ablation or suppression with LHRH agonist treatment 6. No previous hormone therapy for locally advanced or metastatic disease i.e. is hormone therapy naïve for locally advanced/metastatic breast cancer. Previous hormone therapy with anastrozole or letrozole whether as adjuvant therapy or as neoadjuvant treatment is allowed as long as 7. Ribociclib will only be given in combination with an aromatase inhibitor 8. Patients have an ECOG performance status of 0-2 9. Patients will be treated until progressive disease or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner 10. Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle 11. Ribociclib will be otherwise used as set out in its Summary of Product Characteristics (SPC) 	Yes	TA496	20-Dec-17	20-Mar-18
Ruxolitinib	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis	nca	Yes	TA386	23-Mar-16	21-Jun-16

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Sorafenib	The first line treatment of Child-Pugh A locally advanced or metastatic hepatocellular carcinoma where all of the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. ONE of the following applies to the patient: the patient has a confirmed histological diagnosis of hepatocellular carcinoma or a biopsy is deemed to be very high risk or technically not feasible in the patient AND the criteria below are met: a. The decision not to biopsy has been made and documented by a specialist HCC MDM b. The tumour meets the non-invasive diagnostic criteria of hepatocellular carcinoma* c. Data is submitted as part of the ongoing Sorafenib Audit 2. It is expected that OPTION 2 will only apply in exceptional circumstances and it should be noted that responses will be reviewed regularly to ensure that this is the case. *EASL–EORTC Clinical Practice Guidelines: Management, Journal of Hepatology 2012 vol. 56 p 908–943. Non-invasive criteria can only be applied to cirrhotic patients and are based on imaging techniques obtained by 4-phase multidetector CT scan or dynamic contrast-enhanced MRI. Diagnosis should be based on the identification of the typical hallmark of HCC (hypervascular in the arterial phase with washout in the portal venous or delayed phases). While one imaging technique is required for nodules beyond 1 cm in diameter a more conservative approach with 2 techniques is recommended in suboptimal settings.</p> <p>3. Patient must have either metastatic disease or locally advanced disease that is ineligible for or failed surgical or locoregional therapies</p> <p>4. Patient has not received any previous systemic therapy for hepatocellular carcinoma</p> <p>5. Patient must have Child-Pugh liver function class A</p> <p>6. Patient has a performance status of 0-2</p> <p>7. Sorafenib is to be used as a single agent</p> <p>8. Sorafenib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment</p> <p>9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)</p> <p>10. Sorafenib to be otherwise used as set out in its Summary of Product Characteristics</p>	Yes	TA474	06-Sep-17	05-Dec-17
Sunitinib	The treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression where all the following criteria are met:	<p>1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</p> <p>2. The patient has histopathologically proven well differentiated neuroendocrine tumour of pancreatic origin</p> <p>3. The patient has unresectable or metastatic disease</p> <p>4. The patient has exhibited disease progression in past 12 months</p> <p>5. The patient has a performance status of 0-1</p> <p>6. The patient has had no previous treatment with a tyrosine kinase inhibitor.</p> <p>7. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</p> <p>8. Sunitinib will otherwise be used as set out in its Summary of Product Characteristics (SPC).</p>	Yes	TA449	13-May-17	26-Sep-17

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Talimogene Laherparepvec	Talimogene laherparepvec for treating unresectable metastatic melanoma	1. I confirm that an application has been made and the first treatment will be prescribed and administered by a consultant specialist experienced in the treatment of melanoma	No	TA410	28-Sep-16	28-Dec-16
		2. I confirm this treatment will be given by a specialist trained to give intra-lesional injections of talimogene.				
		3. I confirm the patient has cutaneous, subcutaneous or nodal deposit(s) of melanoma which is/are suitable for direct injection but is/are not surgically resectable.				
		4. I confirm the patient has stage IIIb, stage IIIc or stage IVM1a disease according to the AJCC stage criteria of 2009 7th edition and if stage IVM1a disease (ie metastases to the skin, subcutaneous tissues or distant lymph nodes) has a normal serum LDH.				
		5. I confirm the patient has no bone, brain, lung or any other visceral secondaries and if stage IVM1a disease, the serum LDH is not elevated.				
		6. I confirm talimogene has been sanctioned by a specialist melanoma multidisciplinary team which includes an oncologist and a surgeon with expertise in the management of metastatic and locally advanced melanoma, respectively.				
		7. I confirm that talimogene is appropriate for this patient as systemically administered immunotherapies or approved targeted therapies are not considered the best option by the specialist melanoma multidisciplinary team meeting which includes an oncologist and a surgeon with expertise in the management of metastatic and locally advanced melanoma, respectively.				
		8. I confirm that talimogene will only be administered as a single agent and not in combination with systemic therapies eg chemotherapy, targeted agents or immunotherapy unless this is within the context of a Health Research Authority clinical trial.				
		9. I confirm the patient will receive the licensed dose and frequency of talimogene laherparepvec				
Tivozanib	The treatment of advanced renal cell carcinoma where all the following criteria are met:	1. This application is made by and the first cycle of systemic anti-cancer therapy with tivozanib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	No	TA512	21-Mar-18	19-Jun-18
		2. This patient has a confirmed histological diagnosis of renal cell carcinoma with a clear cell component				
		3. The patient has either metastatic disease or inoperable locally advanced disease				
		4. The patient is treatment naïve to systemic therapy and in particular has previously received neither any vascular endothelial growth factor (VEGF)-targeted systemic therapy nor mTOR pathway inhibitor-targeted treatment unless prior treatment with pazopanib or sunitinib has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of progression (see criteria 10).				
		5. The patient has an ECOG performance status of either 0 or 1. A patient with a performance status of 2 is not eligible for tivozanib				
		6. If the patient has brain metastases, then these have been treated and are stable				
		7. Tivozanib is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment				
		8. A formal medical review as to whether treatment with tivozanib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment				
		9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		10. I confirm that the patient has had no prior treatment either with pazopanib or sunitinib unless such prior treatment has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression*. *Patients treated with tivozanib may switch to pazopanib or sunitinib where treatment has had to be stopped early under the same circumstances.				
		11. Tivozanib is to be otherwise used as set out in its Summary of Product Characteristics				

National Cancer Drugs Fund (CDF) List

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Trastuzumab Emtansine	The treatment of HER2-positive locally advanced/ unresectable or metastatic (Stage IV) breast cancer where all the following criteria are met:	<ol style="list-style-type: none"> 1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Progression of her-2 positive locally advanced or metastatic breast cancer 3. Progression during or after the most recent treatment for advanced stage disease or within 6 months of completing treatment for early stage disease 4. Previous treatment with a taxane 5. Previous treatment with trastuzumab 6. Performance status of 0, 1 or 2 7. Left ventricular ejection fraction of 50% or more 8. NOTE: not to be used beyond first disease progression outside the CNS. Do not discontinue if disease progression is within the CNS alone 9. no planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). 10. will otherwise be used as set out in its Summary of Product Characteristics (SPC). <p>Note: To minimise the risk of errors due to the similarity of the product name Trastuzumab Emtansine (Kadcyla) with that of Trastuzumab the recommendations in the Risk Minimisation Plan educational material from the manufacturer should be followed when prescribing, dispensing and administering the product</p>	Yes	TA371	19-Jul-17	17-Oct-17
Trifluridine– tipiracil	Trifluridine–tipiracil for previously treated metastatic colorectal cancer	<ol style="list-style-type: none"> 1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2. I confirm the patient has metastatic colorectal cancer. 3. I confirm that the patient has failed at least two prior regimens* for advanced/metastatic disease. Those patients relapsing during or within 6 months of completing adjuvant chemotherapy can count the adjuvant line as one line of therapy for advanced/metastatic disease. * Prior regimens: fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents. 4. I confirm that the patient is not considered a candidate for all other available therapies. 5. I confirm that the patient has a PS 0 or 1. 6. I confirm the patient will receive the licensed dose and frequency of trifluridine–tipiracil 	No	TA405	24-Aug-16	22-Nov-16

National Cancer Drugs Fund (CDF) List

Version Control

Version No.	Date published	Author(s)	Revision summary
0.1	n/a	D Thomson; P Clark	Initial draft of new CDF list, based on pre-existing national CDF list but updated for changes to the CDF, for review.
1.0	29-Jul-16	D Thomson; P Clark	Final version of new CDF list
1.1	09-Aug-16	P Clark	New addition to CDF list
1.2	18-Aug-16	D Thomson; P Clark	New addition to CDF list and revision of criteria for a number of existing drugs
1.3	24-Aug-16	D Thomson; P Clark	Removal of one drug/indication for baseline funding and date for baseline funding added for existing drugs.
1.4	02-Sep-16	D Thomson; P Clark	Update to Radium criteria and timeline following publication of NICE FAD
1.5	20-Sep-16	D Thomson; P Clark	Removal of two drugs/indications for baseline funding
1.6	27-Sep-16	D Thomson; P Clark	Removal of two drug indications
1.7	04-Oct-16	D Thomson; P Clark	Addition of new CDF drug and date for baseline funding added for existing drugs
1.8	21-Oct-16	D Thomson; P Clark	New addition to CDF list
1.9	25-Oct-16	D Thomson; P Clark	Removal of one drug/indication for baseline funding.
1.10	03-Nov-16	D Thomson; P Clark	Update to eribulin following publication of NICE FAD
1.11	10-Nov-16	D Thomson; P Clark	Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"
1.12	17-Nov-16	D Thomson; P Clark	Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD
1.13	23-Nov-16	D Thomson; P Clark	New addition to CDF list, removal of two drugs/indications for baseline funding and update to Nivolumab timeline following publication of final guidance
1.14	02-Dec-16	D Thomson; P Clark	New addition to CDF list (PEMB1_v1.0); update to neoadjuvant pertuzumab (PER2) criteria.
1.15	12-Dec-16	D Thomson; P Clark	New addition to CDF list (IBR3_v1.0); update to ibrutinib in pretreated CLL (IBR1) criteria.
1.16	21-Dec-16	D Thomson; P Clark	Removal of two drugs/indications for baseline funding; update of five timelines following publication of final NICE guidance; update to pembrolizumab criteria.
1.17	23-Dec-16	D Thomson; P Clark	Removal of one drug/indication for baseline funding; update to pertuzumab criteria
1.18	28-Dec-16	D Thomson; P Clark	Removal of three drugs and indications for baseline funding; removal of pegaspargase.
1.19	12-Jan-17	D Thomson; P Clark	Update to everolimus (RCC) following publication of NICE FAD; update to two timelines following publication of final NICE guidance; update to radium 223 criteria in section B
1.20	10-Feb-17	D Thomson; P Clark	Update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"; update of 2 timelines following publication of final NICE guidance; update to ponatinib following ACD
1.21	02-Mar-17	D Thomson; P Clark	Updates to section A - CET1, CET4, PAN3, PAN1. Updates to section B - Ipilimumab + Nivolumab, Dabrafenib + Trametinib
1.22	21-Mar-17	D Thomson; P Clark	Removal of 5 drugs/indications for routine funding and addition to section B. Update to Ipilimumab + Nivolumab criteria.
1.23	11-Apr-17	D Thomson; P Clark	Removal of 1 drugs/indications for routine funding .
1.24	27-Apr-17	D Thomson; P Clark	Removal of 2 drug/indications for routine funding and update to section B. Addition of two drug/indications following publication of FAD
1.25	28-Apr-17	D Thomson; P Clark	Following publication of ponatinib in CML FAD - incorporation of 2 previous separate sets of criteria into a single set
1.26	02-May-17	D Thomson; P Clark	Replacement of current criteria for brentuximab in HD with new criteria following publication of NICE FAD and update to blinatumomab in children criteria
1.27	12-May-17	D Thomson; P Clark	Addition of 2 CDF drug/indications and updated of 1 CDF drug/indication following publication of FAD
1.28	31-May-17	D Thomson; P Clark	Removal of 1 drug/indication for routine funding and 1 new drug/indication addition following publication of the FAD
1.29	02-Jun-17	D Thomson; P Clark	2 new drug/indications following publication of FAD
1.30	09-Jun-17	D Thomson; P Clark	3 new drug/indications following publication of 2 FADs; update to existing criteria
1.31	15-Jun-17	B Groves; P Clark	Revision to 1 drug/indication following publication of FAD
1.32	30-Jun-17	D Thomson; B Groves	Revision to 1 drug/indication in CDF / two drugs in 4 indications moved from CDF to routine commissioning
1.33	10-Jul-17	P Clark; B Groves	1 new drug/indication following publication of FAD
1.34	24-Jul-17	P Clark; D Thomson; B Groves	1 new drug/indication; two drugs entering baseline commissioning, update to OLA2_v1.1 interim funding status
1.35	04-Aug-17	P Clark; D Thomson; B Groves	1 new drug/indication for interim funding before moving into routine commissioning
1.36	08-Aug-17	P Clark; D Thomson; B Groves	1 drug/indication revised and 1 new drug indication added
1.37	10-Aug-17	P Clark; D Thomson; B Groves	1 drug/indication revised and 1 new drug indication added; update to treatment break criteria throughout; update to 1 drug with date for transition to routine commissioning
1.38	24-Aug-17	P Clark; B Groves	1 indication deleted and replaced with updated and separate child and adult treatment criteria; Removal of 1 drug/indication for routine funding and update to section B; 2 drugs 'available to new patients' status
1.39	31-Aug-17	D Thomson; B Groves	1 indication moved into routine commissioning; 1 indication updated to reflect notice period for registering new patients
1.40	06-Sep-17	D Thomson; B Groves	2 indications updated to reflect the date they move into routine commissioning; 1 indication updated to reflect notice period for registering new patients
1.41	08-Sep-17	P Clark; D Thomson; B Groves	1 new drug in 2 indications added; 1 existing indication updated to reflect expected entry into routine commissioning
1.42	26-Sep-17	P Clark; D Thomson; B Groves	11 indications moved from CDF to routine commissioning
1.43	28-Sep-17	P Clark; D Thomson; B Groves	1 drug/indication added
1.44	05-Oct-17	P Clark; D Thomson; B Groves	1 drug/indication removed; 2 new CDF indications added
1.45	12-Oct-17	P Clark; D Thomson	1 drug/indication revised following interim funding
1.46	13-Oct-17	P Clark; D Thomson	1 new drug/indication entering CDF
1.47	17-Oct-17	P Clark; D Thomson; B Groves	2 drugs/indications moving from CDF to routine commissioning
1.48	01-Nov-17	P Clark; D Thomson; B Groves	1 drug/indication criteria updated
1.49	05-Nov-17	P Clark; D Thomson; B Groves	1 drug/indication criteria removed
1.50	08-Nov-17	P Clark; D Thomson; B Groves	1 drug/indication moved from CDF into routine commissioning
1.51	16-Nov-17	P Clark; D Thomson; B Groves	2 new drug/indications added following publication of FAD
1.52	22-Nov-17	P Clark; D Thomson; B Groves	Notice of removal for 1 drug/indication; treatment criteria clarified for 1 drug/indication; 2 drug/indication titles amended
1.53	05-Dec-17	P Clark; D Thomson; B Groves	2 drugs/indications moved into routine commissioning;

National Cancer Drugs Fund (CDF) List

Version Control(Cont)

Version No.	Date published	Author(s)	Revision summary
1.54	07-Dec-17	P Clark; D Thomson; B Groves	1 drug/indication with interim funding
1.55	08-Dec-17	P Clark; D Thomson; B Groves	1 drug/indication with interim funding
1.56	14-Dec-17	P Clark; D Thomson; B Groves	1 drug/indication split into two indications; 2 drugs/indication updated with dates for expected entry into routine commissioning
1.57	19-Dec-17	P Clark; D Thomson; B Groves	1 new CDF drug/indication; notice given for 2 drugs/indications attracting interim funding which will move into routine commissioning in 90-days; 4 updates to criteria (1 CDF, 3 routine)
1.58	02-Jan-18	P Clark; D Thomson	2 drug/indications moving from CDF to routine commissioning; 4 updates to criteria (1CDF, 3 routine); 1 update to IFA section
1.59	17-Jan-18	P Clark; B Groves	1 drug/indication added to the CDF; 1 drug/indication updated
1.60	18-Jan-18	P Clark; D Thomson; B Groves	1 drug/indication updated
1.61	22-Jan-18	B Groves	1 drug/indication delisted
1.62	01-Feb-18	B Groves	3 drugs for 4 indications updated following NICE final guidance
1.63	09-Feb-18	P Clark; D Thomson; B Groves	1 drug/indication for routine commissioning
1.64	12-Feb-18	P Clark; D Thomson; B Groves	1 drug/indication for routine commissioning
1.65	15-Feb-18	P Clark; D Thomson; B Groves	3 drug/indication for routine commissioning which will receive interim CDF funding; 1 drug/indication moved into routine commissioning; 1 drug/indication with updated treatment criteria
1.66	21-Feb-18	B Groves	2 drug/indications updated
1.67	01-Mar-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF; 1 drug/ indication for routine commissioning which will receive interim CDF funding; 3 drug/indications with updated treatment criteria
1.68	07-Mar-18	D Thomson; D Dwyer	1 indication moved into routine commissioning
1.69	16-Mar-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.70	20-Mar-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.71	21-Mar-18	D Thomson; D Dwyer	2 drugs/indications updated to reflect the date they move into routine commissioning
1.72	28-Mar-18	D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning; 1 drug/indication moved into routine commissioning; 1 drug/indication with updated treatment criteria
1.73	03-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/indication removed
1.74	09-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/ indication for routine commissioning which will receive interim CDF funding
1.75	11-Apr-18	D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning
1.76	19-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/indication with updated treatment criteria
1.77	24-Apr-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.78	25-Apr-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.79	27-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.80	01-May-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.81	04-May-18	P Clark; D Thomson; D Dwyer	5 drugs/indications which will receive interim CDF funding; 2 drugs/indications for routine commissioning
1.82	16-May-18	D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning
1.83	17-May-18	P Clark; D Thomson; D Dwyer	1 drug/ indication for routine commissioning which will receive interim CDF funding
1.84	25-May-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.85	01-Jun-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.86	05-Jun-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.87	13-Jun-18	P Clark; D Thomson; D Dwyer	8 drugs/indications updated to reflect the date they move into routine commissioning; 2 drugs/indications updated to note EMA recommendation; 1 drug/indication with updated treatment criteria
1.88	19-Jun-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.89	26-Jun-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.90	28-Jun-18	P Clark; D Thomson; D Dwyer	1 drug/ indication for routine commissioning which will receive interim CDF funding; 1 drug/indication with updated treatment criteria
1.91	05-Jul-18	D Thomson; D Dwyer	2 drugs/indications with updated treatment criteria
1.92	10-Jul-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.93	12-Jul-18	P Clark; D Thomson; D Dwyer	2 drugs/ indications for routine commissioning which will receive interim CDF funding; 3 drugs/indications moved into routine commissioning; 1 drug/indication with updated treatment criteria
1.94	13-Jul-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning;
1.95	20-Jul-18	P Clark; D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning; 1 drug/ indication for routine commissioning which will receive interim CDF funding; 1 drug/indication with updated treatment criteria
1.96	25-Jul-18	P Clark; D Thomson; B Groves	1 drug in 2 indications entering a CDF managed access period
1.97	03-Aug-18	D Thomson; D Dwyer	1 drug/indication with updated treatment criteria
1.98	09-Aug-18	P Clark; D Thomson; D Dwyer	2 drugs/indications for routine commissioning which will receive interim CDF funding; 2 drugs/indications with updated treatment criteria; 3 drugs/indications updated to reflect the date they move into routine commissioning
1.99	14-Aug-18	B Groves; P Clark; D Thomson	1 drug/indication moved into routine commissioning; 1 drug/indication moved back to the CDF list
1.100	24-Aug-18	P Clark; D Thomson; D Dwyer	1 drug/indication for routine commissioning which will receive interim CDF funding; 3 drugs/indications with updated treatment criteria; 2 drugs/indications updated to reflect the date they move into routine commissioning
1.101	31-Aug-18	P Clark; D Thomson; D Dwyer	2 drugs/indications with updated treatment criteria; 1 drug/indication updated to reflect the date it moves into routine commissioning

National Cancer Drugs Fund (CDF) List

Changes to recent versions

General or criteria changed	Summary of changes
Changes to version 1.101	
Ibrutinib - routine	Ibrutinib for the treatment relapsed/ refractory chronic lymphocytic leukaemia split into two forms in light of recent update to eligibility criteria
Ibrutinib - routine	Treatment criteria (5, 6 & 7) updated for ibrutinib for the treatment of chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
LUT1_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 27-Nov-18
Changes to version 1.100	
CABO3_v1.0	Recommended for routine commissioning, receiving CDF interim funding
Cabozantinib - routine	Treatment criteria (9) added
DIN1_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 20-Nov-18
DIN2_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 20-Nov-18
BRE5_v1.3	Treatment criteria (4) updated
BRE6_v1.2	Treatment criteria (4) updated
Changes to version 1.99	
ATE2_v1.0	Moved into routine commissioning - section B of list
BEN6_v2.1	Moved back to the CDF list (section A) to reflect that this is still commissioned via the CDF
Changes to version 1.98	
INO1_v1.0	Recommended for routine commissioning, receiving CDF interim funding
INO2_v1.0	Recommended for routine commissioning, receiving CDF interim funding
Blinatumomab - routine	Treatment criteria (3 & 9) updated
Blinatumomab - routine	Treatment criteria (3 & 9) updated
ALE1_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 06-Nov-18
LN2_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 06-Nov-18
SOR2_v3.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 06-Nov-18
Changes to version 1.97	
BEV2_v1.4	Treatment criteria around treatment breaks (10) updated
Bendamustine - routine	Duplicate entry deleted
Changes to version 1.96	
PEMB5_v1.0	Recommended for the CDF
PEMB6_v1.0	Recommended for the CDF
Changes to version 1.95	
PEMB2_v1.1	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 16-Oct-18
LUT1_v1.0	Recommended for routine commissioning, receiving CDF interim funding
Tivozanib - routine	Treatment criteria (4) updated
Changes to version 1.94	
ATE3_v1.0	Moved into routine commissioning - section B of list
PEMB4_v1.0	Treatment criteria updated reflecting the change to the European Medicines Agency's (EMA) marketing authorisation; 1 drug/indication with updated treatment criteria
Changes to version 1.93	
DIN1_v1.0	Recommended for routine commissioning, receiving CDF interim funding
DIN2_v1.0	Recommended for routine commissioning, receiving CDF interim funding
BEN1_v2.0	Moved to routine commissioning following a positive recommendation from CPAG on 8 July 2018
BEN6_v2.1	Moved to routine commissioning following a positive recommendation from CPAG on 8 July 2018
BEN2_v2.0	Moved to routine commissioning following a positive recommendation from CPAG on 8 July 2018
ATE1_v1.1	Treatment criteria updated reflecting the change to the European Medicines Agency's (EMA) marketing authorisation
Changes to version 1.92	
AVE2_v1.0	Moved into routine commissioning - section B of list
Changes to version 1.91	
Panitumumab - routine	Note around treatment breaks updated
Cetuximab - routine	Note around treatment breaks updated
Tivozanib - routine	Duplicate entry deleted
Changes to version 1.90	
ALE1_v1.0	Recommended for routine commissioning, receiving CDF interim funding
Ceritinib - baseline	Treatment criteria (11) updated